The Effects of Lead Exposure at Different Stages of Life on Neurobehavioral and Metabolic Outcomes. by Huang, Siying
 
THE EFFECTS OF LEAD EXPOSURE AT DIFFERENT STAGES OF LIFE ON 








A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Environmental Health Sciences) 











Professor Karen Peterson, Chair 
Assistant Professor Sung Kyun Park 
Assistant Professor Brisa N Sánchez 





















This dissertation is dedicated to my grandma, who has been and always will be 







































My committee had played an indispensible role in the growth of my career. I 
would like to thank each of them for their patience and guidance every step of the way. 
Working with them has been inspirational and joyful even when facing challenges. I 
came into the science world as a young person with all kinds of hope for working in 
science and my committee has helped me to progress and develop. They never 
stopped challenging me with constructive advice and questions, which expanded my 
horizons and propelled my thoughts growing comprehensively. They are my role models 
in the career development and philosophers of life that I would look up to. I am very 
grateful to these people who have made my dream come true in such a nurturing 
environment. 
Family has always been oceans away. Yet it has been the biggest inspiration for 
my pursuit. I would like to express my gratitude to these people who never stopped 
planting hopes and keeping faith in me. Their love fulfills my heart. Their faith in me 
filled me with strength to carry on through out these years. I love them, deeply. This is 
the greatest milestone I ever achieved in my life to share with them. Yet, my 
gratefulness to these people is beyond any achievement I could make. 
Supports from friends made me never felt alone in this journey. We learned from 
each other in school and in life. Together, we went through the rainy days and we 
rejoiced as the sun comes out. They have made this foreign town into a place I would 
 
 iv 
like to call home. Thank you all for adventuring with me along this journey. Thank you 
for abiding with me and lending helping hands to me during this dissertation-writing 
period. Thank you, Excel queen, Indian spice, Tree climber, Garden angel, Captain, 
Etta’s papa, Judo master, Curious mind, Pickle queen, Suppa-Summa and many other 
here names concealed beautiful souls.   
Last but not the least, I would like to express my appreciations to the department 
very owned administrative team and our collaborators at the Harvard University and in 
Mexico City.  Their supports kept me progressing; their dedications to work encouraged 

















TABLE OF CONTENTS 
Dedication....................................................................................................................... ii!
Acknowledgements ...................................................................................................... iii!
List of Tables ................................................................................................................vii!
List of Figures..............................................................................................................viii!
Chapter 1  
Lead Toxicity and Lead Exposure Measurements......................................................1!
Lead Exposure and Public Health Significance................................................................... 1!
Lead Toxicity ........................................................................................................................... 3!
Biomarkers for Lead Exposure Measurement ..................................................................... 6!
Lead Absorption and Distribution in the Body....................................................................... 6!
Biomarkers for Short-term Lead Exposure ........................................................................... 7!
Biomarkers for Cumulative Lead Exposure .......................................................................... 9!
Decisions on Biomarker Selections .................................................................................... 13!
Dissertation Overview .......................................................................................................... 15!
Figures ................................................................................................................................... 18!
References ............................................................................................................................ 22!
Chpater 2  





Lead Exposure Measurements ........................................................................................... 33!
Outcome Measurements..................................................................................................... 34!
Measurement of Confounders ............................................................................................ 36!
Statistical Analyses ............................................................................................................. 36!
Results ................................................................................................................................... 39!
Discussion............................................................................................................................. 42!
Timing of Psychobehavioral Development.......................................................................... 45!





Chapter 3  
The Potential Influence of Variants of the SNCA Gene on the Impact of Cumulative 






Retrospective Lead Exposure............................................................................................. 70!
Other Information ................................................................................................................ 70!
Genotyping and Quality Control.......................................................................................... 71!
Statistical Analyses ............................................................................................................. 71!
Results ................................................................................................................................... 73!
Discussion............................................................................................................................. 78!
!-synuclein and PD ............................................................................................................ 79!




Chapter 4  






Bone Lead Assessment .................................................................................................... 113!
Type 2 Diabetes Identification........................................................................................... 113!
Other Information .............................................................................................................. 114!
Statistical Analyses ........................................................................................................... 114!
Discussion........................................................................................................................... 120!
Justification of the Decisions in Survival Analyses ........................................................... 120!



















LIST OF TABLES 
Table 2.1 Characteristics of Study Participants by Cohorts ...........................................51!
Table 2.2 Lead Effects from Cord Blood Lead Models in Cohort 2................................53!
Table 2.3 Lead Effects from Gestational Blood Lead Models in cohorts PL and SF .....54!
Table 3.1 Covariate Distributions in the Included and Exclude Subjects by PD Status .85!
Table 3.2 Allele Frequency in Case and Control Groups...............................................86!
Table 3.3 Genotype Frequency between Cases and Controls ......................................87!
Table 3.4 Markers’ Main Effects and Interaction Effects from Tibia Lead Models .........88!
Table 3.5 Markers’ Main Effects and Interaction Effects from Patella Lead Models ......89!
Table 4.1 Characteristics of Study Population at Baseline in T2DM and Non-T2DM 
Groups .....................................................................................................127!
Table 4.2 Comparison of Characteristics in T2DM Subjects in the Final Dataset by Birth 
Cohorts .....................................................................................................128!
Table 4.3 Comparison of Characteristics in T2DM Subjects by Patella Lead Groups 129!
Table 4.4 Comparison of Coefficients in Tibia and Patella Lead Models.....................130!
Table 4.5 Hazard Ratios and 95% Confidence Intervals in the Final Models ..............131!
Table S 2.1 Comparison between Included and Excluded Subjects in Cohort 2 ...........55!
Table S 2.2 Comparison between Included and Excluded Subjects in Cohort 2 PL and 
Cohort 3 Combined.....................................................................................56!
Table S 3.1 Tibia Lead Main Effects in the Final Dataset ..............................................90!
Table S 3.2 Gene-Environment Independence Test Results.........................................91!
Table S 3.3 Standardized Coefficients of Main Effects of Bone Lead from Gene-
Environment Interaction Models .................................................................92!


















LIST OF FIGURES 
Figure 1.1 Structure of X-Ray Fluorescence Machine ...................................................18!
Figure 1.2 Configuration of K-Shell X-Ray Fluorescence Machine................................19!
Figure 1.3 Working Interface of Genie 2000 MCA .........................................................20!
Figure 1.4 Scope of the Dissertation..............................................................................21!
Figure 3.1 Physical Distance of 14 Markers in SNCA Gene ..........................................93!
Figure 3.2 Bone Lead Levels and Probability of PD by SNCA Genotypes ....................95!
Figure 4.1 Event Timeline in NAS (Frequency Density Plot) .......................................133!
Figure 4.2 Survivor Effect (T2DM Onset vs. Birth Year) ..............................................134!
Figure 4.3 Hazard Ratios vs. Tibia Lead Levels ..........................................................135!
Figure 4.4 Hazard Ratios vs. Patella Lead Levels .......................................................136!
Figure S 2.1 Correlations among Lead Exposures in Cohort 2 (BI and PL) ..................57!
Figure S 2.2 Correlations among Lead Exposures in Cohorts PL and SF combined ....58!
Figure S 3.1 –Log10 (p value) from Hardy-Weinberg Tests ............................................96!
Figure S 3.2 High Linkage Disequilibrium Pairs.............................................................97!
Figure S 3.3 –Log10 (p Value) of Fisher Exact Tests at 14 Loci .....................................98!
Figure S 3.4 –Log10 (p Value) of Cochran-Armitage Tests at 14 Loci............................99!
Figure S 3.5 Interaction Effect Estimates in Tibia Lead Models (Unconditional Maximum 
Likelihood vs. Empirical Bayes Likelihood Estimates) ..............................100!
Figure S 3.6 Interaction Effect Estimates in Patella Models (Unconditional Maximum 





1. CHAPTER 1 LEAD TOXICITY AND LEAD EXPOSURE MEASUREMENTS 
Lead Exposure and Public Health Significance  
Lead poisoning is a well-recognized public health concern, and lead pollution 
remains a serious issue worldwide. In 2003, WHO estimated that there were 120 million 
people worldwide who had blood lead levels greater than 10 !g/dL, and 240 million 
people had blood lead levels exceeding 5 !g/dL1. A meta-analysis2 mapped 242 
populations from 1011 studies and datasets worldwide and identified 57 populations 
that had average blood lead levels exceeding 10 !g/dL, the CDC level of concern in 
children3. The main sources of lead pollution vary across countries; the most common 
sources of lead exposures come from metal smelters, leaded gasoline, lead paint, 
battery recycling and lead-glazed pottery. For instance, lead gasoline is the main source 
of lead pollution in Bangladesh and Senegal; family-based battery lead recycling is the 
main problem in Mexico, the Caribbean Islands, and India; lead contaminated food 
containers such as lead glazed pottery and lead solder in aluminum cans are major 
sources of lead pollution in Mexico and Honduras 2, 4. In China, the lack of 
environmental emission control of industrial wastes results in regional lead 
contamination at exceeding levels. Between 1994 and 2004, about 34% of Chinese 
children had blood lead levels higher than the WHO’s recommended limit 5. 
The main sources of lead pollution in the United States came from leaded 
gasoline, lead paint from buildings built before 1980, and lead water pipes6. The 
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concentrations of lead in occupational settings are much higher than those in the living 
community 7. Having recognized the detrimental effects of lead, the US Environmental 
Protection Agency (EPA) in 1973 initiated a series of actions to phase out lead from the 
daily use products, e.g., the removal of lead from gasoline and paint 8. It was not until 
1996 that the final step was taken by the EPA to eliminate lead from gasoline8. Yet, the 
lead the residuals in urban soil in the US remains a source of concern for lead 
poisoning6.  
In general, lead levels at or above 150 µg/dL in whole blood may cause 
irreversible and fatal consequences9, 10.  At lower levels such as 30-40 µg/dL, lead 
poisoning results in the impairment of multiple systems such as the nervous system in 
the susceptible populations, including in children and elderly11. Lead poisoning is also 
correlated with premature birth and intrauterine growth retardation12-14. Chronic lead 
poisoning is associated with renal function impairment15, cardiovascular diseases16, 
infertility17, 18 and pathological neurodegeneration 19. The clinical symptoms of lead 
poisoning are not distinct, which make the diagnosis difficult. The long-term effects from 
cumulative lead exposure are intertwined with aging process, posing a great challenge 
for scientific investigation. 
Lead poisoning causes adverse outcomes not only limited to human health, but 
also to economies by virtue of loss in workforce, compensation in medical care, and 
long term reduction in intelligence20. Reducing environmental lead contaminants can 
result in economic benefits. It is estimated that a lowering the mean blood lead in the 
population by 1 µg/dL could save approximately $3.5 billion per year in reduced 
healthcare costs from lead poisoning in the US 21, 22. In summary, environmental lead 
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exposure still poses current public health concern.  Research and actions should be 
taken in order to better characterize and control this persistent hazard.  
Lead Toxicity  
In the body, lead reacts with a variety of molecules at the cellular level.  
According to Nieboer and Richardson’s classification (1980), lead belongs to Class B 
(Pb2+) and Borderline class (Pb4+) 23. This thermodynamic characteristic of lead 
suggests lead ions have a high binding affinity with a broad range of ligands. In 
particular, lead binding selectively favors nucleophilic ligands such as sulfhydryl, amine, 
phosphate and carboxyl groups. Thiolate, which is abundant in many functional 
proteins, has highest the affinity with lead. 
One way that lead interferes with the cellular machinery is by inducing oxidative 
stress. This has a direct impact on cell membranes, causes changes in with the enzyme 
"-aminolevulinic acid dehydratase ("-ALAD) and inhibits reductase. When binding with 
proteins, lead can cause changes in conformation or occupy a variety of binding sites, 
thus preventing subsequent reactions. Copropohyrinogen oxidase (CO) is one of the 
proteins that are affected by lead. When binding with Pb2+, CO enzyme activity is 
inhibited through structural change, which results in instability of membrane integrity 24.  
Alternatively, in other proteins, lead can outcompete other essential metals cofactors at 
the bioactive binding sites, deactivating proteins. For example, Pb2+ displaces Zn2+ from 
the metallothionein (MT) and inhibits synaptic membranes functions maintained by the 
Zn2+- MT binding structure 25.  
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Lead can also induce oxidative stress with the involvement of mitochondrial 
distress. With a higher binding affinity, Pb2+ outcompetes Ca2+ at the plasma membrane 
Ca2+ transport channel. The permeability of Pb2+ at the cell membrane is tenfold of Ca2+ 
26. Unlike Ca2+, Pb2+ uptake does not appear to reach saturation 26, 27. Pb2+ replaces 
Ca2+ at both of the Ca2+-ATPase sites and at voltage sensitive Ca2+ channels, depletes 
Ca2+ in the mitochondria by impeding Ca2+ uptake into mitochondria and by stimulating 
Ca2+ efflux from mitochondria 28, 29. Alternatively, lead can impose mitochondrial stress 
via inhibition of heme production.  Pb2+ can block catalytic sites that contains vicinal 
thiol groups in the enzyme heme synthetase 25 and  result in the reduction in ATP 
production. Insufficient ATP production in mitochondria in turn creates free radical 
oxygen species (ROS).  
Independent of mitochondrial stress pathways, lead-induced oxidative stress can 
be observed in the peripheral tissues 30, 31. For instance, lead can result in the 
elongation of arachidonic acid in fat tissue 32. Over 80% of lead in erythrocytes binds to 
"-ALAD. Pb2+ replaces Zn2+ at SH sites and inhibits the subsequent binding with "- 
aminolevulinic acid ("-ALA). This leads to accumulation of "-ALA in the cell cytoplasm. 
"-ALA is auto-oxidative at pH 7.0-8.0 and can generate free radicals 33. "-ALAD 
bioactivity can be affected in blood lead levels as low as 5 !g/dL. Approximately 50% of 
"-ALAD activity inhibition occurs at 16 !g/dL in whole blood, whereas 90% of the 
enzyme activity inhibition is observed at 55 !g/dL 34. Antioxidant molecules, such as 
glutathione (GSH), glutathione reductase (GR), glutathione peroxidase, and superoxide 
dismutase are also susceptible to lead. Lead binds at sulfhydryl sites in GSH and GR 
 
 5 
and reduces the amount of bioactive enzymes 35, 36. Reduction in these bioactive 
antioxidants weakens defenses against oxidative stress.  
Excessive elevation in oxidative stress can have severe consequences to the 
cell. Free radicals have a wide range of intracellular targets, such as nuclear and 
plasma membranes, which are needed to maintain cell function and survival 37 38. The 
destruction of these structures can lead to cell apoptosis or necrosis35.  For instance, 
lipid peroxidation at cell membrane results in structural derangement and alters 
phospholipid bilayer fluidity32. Additionally, oxidative stress affects enzyme activities, 
such as Na+-K+-ATPase, cytochrome oxidase, and succinic dehydrogenase. The 
dysfunction of these enzymes causes increase in permeability of membranes, which 
makes the organelles unable to contain constituents 39. For instance, the instability of 
lysosome membranes causes the release of acid hydrolases, which can degrade 
intracellular constituents and cause cell lysis40. 
In addition, lead disrupts intracellular electrolyte gradients, which could attract 
water fluxing into the cell and cause osmotic lysis41. For example, in the endoplasmic 
reticulum, the presence of Pb2+ induces Ca2+ release from cytoplasmic organelles and 
results in elevated Ca2+ concentrations in the cytoplasm27. This leads to acute elevation 
of intracellular osmotic pressure and formation of cell edema. Cellular edema is 
especially critical clinically when it occurs in the central nervous system. Severe 
cerebral edema can result in the herniations in the midbrain, a life threatening condition.  
In summary, lead can interfere cellular machinery by interacting with proteins, 
mimicking calcium activities and creating oxidative stress. 
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Biomarkers for Lead Exposure Measurement 
Lead Absorption and Distribution in the Body  
Primary routes of lead exposure in humans are inhalation and ingestion. In 
general, 40 to 50% of inhaled lead deposits in the lung. A very small fraction of inhaled 
lead is trapped in the upper respiratory tract and can be swallowed. Compared with 
intestinal absorption, the lung absorbs lead more efficiently42. However, the absorption 
rate in the lung or intestines increases to approximately 50% in infants and in people 
who are fasting43, 44. Deficiency of other electrolytes also facilitates lead absorption 45,46. 
Around 95% of lead in circulation is sequestered in red blood cells, leaving a small 
fraction of inorganic lead in the plasma that can be transferred into surrounding 
tissues46. The mean biological half-life of blood lead is about 40 days 47.  
Lead from blood is incorporated into calcified tissues such as bone. The fraction 
of lead deposited in bones can persist for years 48. Approximately 70% of the total body 
burden of lead in children is carried in the skeletons and up to 95% in adults 49. Lead in 
bones can be released back into circulation. Depending on bone turnover rates, the 
half-life of cortical bone lead is several decades and about eight years in trabecular 
bones 50. Bone lead release is more prominent during intensive bone turnover periods, 
such as during skeletal growth, pregnancy and osteoporosis51.  
Throughout the years of lead toxicity investigations, many biomarkers have been 
developed and tested for the purposes of screening, biomonitoring or clinical diagnosis. 
Given the biokinetics of lead in the body, biomarkers from different tissue types can be 
used to characterize lead exposure as a function of the timing of exposures. Lead can 
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be detected in blood, urine, nails, hair, soft tissues and bones. Blood, urine and bone 
lead measurement are discussed below, given these comprise specific exposure 
measurements used in the projects in the following chapters.  
Biomarkers for Short-term Lead Exposure  
Blood Lead Measurements   
Whole blood is the primary biological fluid that has been used to assess lead 
exposure assessment in lead studies. Whole blood lead reflects both intracellular and 
extracellular lead levels. It does not serve as an index for immediate lead exposure but 
can reflect recent exposure for up to 30 days 52. Whole blood lead levels also reflect 
lead mobilization from bone to blood, dominantly from trabecular bone 53.  Many 
analytical approaches have been applied for whole blood lead assessment across lead 
studies. A recent widely adopted method is inductively coupled plasma mass 
spectrometry (ICP-MS). This method uses commercially available standard blood 
sample as the reference for quality controls. The intra-individual variation is controlled at 
less than 5% with detection limit at 1µg/dL. The use of whole blood lead measurement 
approach is relatively resistant to contamination issue at the pre-analytical phase and 
during laboratory sample processing. With this assay, the limitation of detection is 
relatively low and concentrations of lead in whole blood are highly measurable. It is cost 
efficient with a cost of 4 to 64 USD per sample.54. 
Plasma lead levels, on the other hand, reflect the bioactive fraction of lead that 
can be transferred across cell membrane and can have direct toxic effects on cells. The 
ICP-MS method allows the measurement of lead in plasma with detection limit at 0.1 
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µg/dL. Theoretically, plasma lead would be an ideal biomarker for studies of lead 
toxicity. However, it is difficult to achieve satisfactory accuracy in the fieldwork setting 
due to many technical issues arising from this measure. First, plasma separation has to 
be performed soon after the blood specimen has been collected because intracellular 
lead can be released into the plasma via hemolysis that occurs shortly after blood 
collection. Even mild hemolysis could increase plasma lead level up to 30% 55. 
Secondly, lead concentrations in plasma make up less than 1% of whole blood lead, 
which imposes greater requirements for the lower detection limit and stringent sample 
handling procedure in the pre-analytical phase to avoid background contamination.  
Thus, characterizing lead levels in plasma from low environmental exposure levels may 
not provide valid results and may lead to exposure misclassification. Thirdly, measuring 
plasma lead requires the highest purity grade of analytical reagents and special metal-
free collecting tubes. Currently, many of these issues have not been completely 
resolved56. These issues also increase the cost for sample processing and make it more 
expensive compared to the cost of whole blood measurement (approximately 38- 127 
USD), especially when more sensitive detection limit is demanded 54.  
Urinary Lead Measurement  
Urinary lead reflects the lead component that has diffused from plasma and is 
filtered out through kidneys. Lead mobilized from bones contributes to urinary lead 57. 
Urinary lead concentration is subject to biological variations involving glomerular 
filtration functions and plasma lead levels. Urinary lead may serve as a proxy for plasma 
lead after adjustment for creatinine excretion. The procedure of urine collection for lead 
measurement is non-invasive and samples are easy to obtain for epidemiologic studies. 
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However, contamination of urine samples from dust particles and the precipitation of 
urate salts can affect the estimation of urinary lead levels 56. 
Biomarkers for Cumulative Lead Exposure  
The half-life of bone lead ranges from years to decades. Bone lead as 
biomarkers for retrospective lead exposures is well recognized in research settings for 
studying the toxicity from cumulative lead exposures. Bone lead concentration can be 
measured in a variety of approaches. Among these methods, X-ray fluorescence (XRF) 
spectroscopy is the primary choice in the studies of human subjects. 
XRF Photon-physics Mechanism  
X-ray fluorescence is a non-invasive bone lead measurement procedure using 
low dose radiation (30mCi) 58. The current generation of XRF uses 109Cd isotope as a 
point excitement source 59. It generates silver X-ray at an energy spectrum of 88 keV. 
This energy level provokes photoelectric interaction that can knock off a K electron or 
an L electron.  Subsequently, an outer shell electron fills the vacancy and emits X-ray 
fluorescence. Depending on the metal-specific inter-shell transition, the energy level of 
X-ray varies. For example, for a lead K electron transition, the most common energy 
levels are 72.8 keV, 75keV, and 85 keV, which correspond to Pb K#2, Pb K#1 and Pb 
K$13 transitions.  Compared to L-XRF, K-XRF requires higher energy excitement and 
suffers less from signaling attenuation by skin shielding. Due to the deep penetration 
capability, K-XRF performs better in terms of capturing the lead concentration dynamics 
across bone sections compared to L-XRF58. In terms of safety, the absorbed organ 
equivalent dose for K-XRF is slightly higher than L-XRF (4.0 µSv vs.2.9 µSv). However, 
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the health risk from this additional radiation exposure are considered minor 60. Given the 
advantages of the K-shell XRF method, the bulk of research on human subject bone 
lead concentration measurements preferentially adopts K-XRF method. 
Working Flow of XRF Machines  
Figure 1.1 and Figure 1.2 illustrates the working flow of a K-XRF machine. The 
photoelectric interaction is provoked by 109Cd source. The Germanium HP detector 
captures the energy emission during machine “live time”. The signal is amplified and 
transferred to the computer for analytical use. Photoelectric events in lead atoms are 
collected and counted over a fixed period of time (30 minutes in real time in our 
studies). Meanwhile, the signals from calcium, carbon, oxygen and Compton scattering 
edges constituting the reference coherent peak (coh) are also collected. Collected data 
are analyzed with Canberra Genie 2000 Multichannel Analyzer (MCA) software (Figure 
1.3). The 109Cd isotope source resolution is tested before examining human subjects. 
System calibration is carried out using plaster-of-Paris phantoms. The phantom acrylic 
tubes are %” thick, which mimics human skin thickness at tibia midpoint. It also contains 
a mixture of lead and calcium sulfate dehydrate (CaSO42H2O) that resembles the 
chemical components of bones.  Nine plaster-of-Paris phantoms with lead 
concentrations marked as 0 parts per million (PPM), 5PPM, 10PPM, 15PPM, 25PPM, 
35PPM, 50 PPM, 75PPM, and100PPM are used to construct a calibration curve. A 
coherent peak (coh)/reference peak is collected during the calibrations. In order to 
derive the lead peak, the background peak counts are subtracted from the total peak 
counts. Therefore, in the cases of very low lead concentrations, negative peak counts 
may be generated. Calibration lines for #1 and $1 peaks are calculated by plotting #/coh 
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and $/coh ratios against lead concentration. The subject’s lead concentration is derived 
by fitting #/coh and $/coh ratios onto a calibration line with correction factors 59.  
Measurement Procedure  
The K-XRF equipment is kept in a dust-free environment in order to reduce 
background noise during the measurement. A metal free chair with a leg stabilization 
device is provided to the study subject. The study subject is asked to sit still and to wear 
a lead free radiation protective apron while being measured. The tibia measurement is 
collected at the shinbone, which is located at the midpoint between inner ankle and tibia 
plateau connection. Patella measurements are collected at the point where the 
excitement source is perpendicular to the keen cap. The point of 109Cd source should be 
kept about two or three centimeters away from the target organ.  
Measurement Accuracy  
There are several factors during preparation measurement that may contribute to 
measurement uncertainty levels. In the calibration stage, analytic choices in 
constructing calibration lines may slightly affect accuracy and precision of the 
measurement later taken in human subjects 59. During the measurement, an increased 
proportion of dead time during data collection period results in the loss of photoelectric 
event counts that can be received by the detector and greatly impacts the uncertainty 
levels. Depletion of 109Cd source can affect background peak distributions 61-63. 
Additionally, excessive movement by the study subject during measurement may 
contribute to considerable amounts of uncertainty.  
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Measurement quality characteristics are related to biological specimens. 
Because bone lead concentration is derived from the background peak that mainly 
contains calcium, the measurement uncertainty is largely related to the features of 
bones, such as bone density and bone structure. Less mineralized bone, often seen in 
active bone turnover stages, e.g., during rapid skeletal growth, pregnancy and 
osteoporosis, renders weak signaling of the calcium reference. Furthermore, due to 
differences in mineral kinetic activities between trabecular and cortical bones, the 
measurement variability of these two types of bones behaves differently. Because 
cortical bones tend to be more mineralized than trabecular bones, the uncertainty levels 
for cortical bone are narrower than those of trabecular bone. Even within the same type 
of bone tissue, the bone lead density exhibits concentration gradient cross-sectionally. 
Newly formed bone layer itself (close to bone marrow side) tends to be more similar to 
low lead components rather than peripheral surface bone 64, 65.  The variability of K-XRF 
measurement increases with true bone lead concentrations regardless of calibration 
and calculation approaches 66. With the current improvements in technology, the 
uncertainty arising from these factors can be greatly reduced, yet they cannot be 
eliminated.  
Estimated measurement uncertainty is equivalent to standard deviation from 
repeated measures of same subject at same site and is derived by goodness of fit 
calculation of scatter in the XRF peaks. For quality control, estimates with uncertainty 
larger than 10 µg/g for tibia lead measurements and 15 µg/g for patella lead 
measurements are considered invalid. Each estimate is reported as a point of 
measurement ± the uncertainty. If the true bone lead concentration is close to zero, the 
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estimate varies above and below zero, in which case, at a single measurement could 
produce a negative point estimate. When reporting results back to the study subject, a 
detection limit (3-fold of standard deviation of blank phantom) is used. However, 
considering the statistical bone lead level distribution in a study population, negative 
values of point estimates are preserved 67, 68.   
Decisions on Biomarker Selections  
Biomonitoring for lead exposure reflects the toxico-dynamic nature of lead 
burden as a function of recent and/or retrospective exposures. Thus, the appropriate 
selection and measurement of lead exposure biomarkers is of particular importance for 
better understanding of the health outcomes from lead exposure with regard to inter-
relationship among biomarkers and the timing of exposures.  
Interrelationships between Lead Biomarkers  
Plasma and urinary lead levels are linearly correlated with each other and both 
are exponentially associated with whole blood lead level 69. Due to the limit of renal 
excretion, however, as the exposure level elevates, urinary lead is disproportionally 
associated with plasma lead 56. It is also observed in occupationally exposed 
populations that plasma and urinary lead levels are linear associated with bone lead 
levels69. 
There are several factors that can affect the lead exchange between plasma and 
whole blood as reflected by ratio of plasma to whole blood lead levels (P-Pb/ B-Pb). For 
instance, ALAD gene variants modify the binding affinities between lead and red blood 
cells.  Meta analysis has shown that ALAD minor allele carriers in occupationally 
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exposed populations have higher lead levels as measured in whole blood 70. Another 
study found that minor allele carriers presented with higher P-Pb/ B-Pb ratios 71. 
Additionally, pregnant woman with ALAD wild type, relative to non-pregnant women, 
had a 2-fold increase in plasma lead and 3-fold increase in the percentage of Pb-P/Pb-B 
ratio72. This could be due to the fact that lead is released back into circulation during 
active bone mobilization in pregnancy. As lead-erythrocyte binding reaches saturation, 
the excess lead flows into the extracellular plasma space.  
Short-term vs. Long-term Lead Exposure Measurement  
As our understanding of lead’s effects on health outcomes grows, the timing of 
exposure is of particular focus. Therefore, the choice of biomarkers in the context of 
timing of exposures is critical. Biomarkers mentioned in the foregoing sections such as 
blood and urinary lead measurements are recognized as reliable indicators of recent 
lead exposure. A critical application of short-term exposure measurement is the 
construction of an exposure matrix that offers a higher resolution of cumulative 
exposure levels with serial short-term measurements 52. This method may outweigh the 
bone lead by providing more accurate long-term exposure dose 73 and by identifying the 
critical windows of exposures.  
Under conditions that lack historical blood lead assessment bone lead serves as 
a good indicator of retrospective lead exposures. By virtue of distinct toxicokinetic 
features in cortical and trabecular bones, one can characterize the temporal pattern of 
exposures. Specifically, tibia lead is more indicative of lead accrued from environmental 
exposure, whereas patella lead is more relevant to the secondary endogenous lead 
exposure53, 74. Studies integrating information from biomarkers of bone resorption 
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activities, such as urinary type I collagen cross-linked N-telopeptides (NTx) levels75, can 
be used to confirm of endogenous exposure levels74, 75 . 
Strength of Long-term Monitoring Lead Exposures 
Cumulative measures of lead exposure dose may be the most crucial 
determinant of some forms of toxicity. When using short-term exposure indicators to 
predict health outcomes, the effect estimates may be confounded by previous 
unmeasured episodes of exposures. Additionally, the exposure at a specific time point 
itself may have a weak the biological relevance with the health outcome. These issues 
are particularly prominent when studying diseases that occur in late life73. Integrating 
exposure history would not only be beneficial in gaining statistical power but also 
provide evidence of long-term effect from accrued lead exposure that cannot be 
observed in a short period of time. Further examples with respect to the strength of 
cumulative lead exposure indicators are illustrated in the three projects in this 
dissertation.   
 Dissertation Overview 
This dissertation focuses on the health effects from lead exposure at different 
stages of life, as graphically represented in figure 1.4. Despite the impressive body of 
evidence showing the toxic effects of lead on neurodevelopment in early life76-79 and 
chronic conditions in late life15, 16, 19, 80, my goal is to further deepen my understanding of 
how the timing of exposures influence health. In particular, I am focusing on the impact 
of lead on behavioral development, interaction of lead with genetic components on 
neurological degenerative disease development and a novel mechanism relating lead to 
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metabolic disorders, such as Type 2 Diabetes Mellitus (T2DM). Three individual projects 
from three epidemiological studies listed in the following chapters comprise this 
dissertation: Early Life Exposure in Mexico to ENvironmental Toxicants study 
(ELEMENT), Normative Aging study (NAS), and Gene-Environmental Metal exposures 
on Parkinson’s Disease study (GEM-PD).  
First, the purpose of Chapter 2 is to explore the influence of lead exposure in 
utero and in early life (birth to early adolescence) on psychobehavioral development. 
This analysis is embedded in the previously established Harvard-Mexico Project on 
Fetal Lead Exposure, Risks and Intervention Strategies (FLERIS) study in Mexico City. 
This analysis examines the associations between early life lead exposures and 
psychobehavioral outcomes by taking advantage of longitudinal exposure 
measurements, accounting for the intercorrelations among consecutive lead exposures. 
The analysis models the tendency of internalizing and externalizing problems, social 
behavioral problems and attention deficit hyperactivity disorder (ADHD)-like behaviors 
as behavioral outcomes. 
Next, Chapter 3 studies on lead effects on neurodegenerative process in the 
central motor control system. It explores the etiology of Parkinson’s disease (PD) from 
the perspective of gene-environment interactions. This analysis utilizes a case-control 
study conducted in Boston, Massachusetts. Both the main effects and interaction effects 
of the genetic variants of SNCA gene were examined in this analysis. The research 
questions whether SNCA genetic variants modify the effect of lead on the odds of 
developing Parkinson’s disease.  
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Finally, the aim of Chapter 4 is to explore the effect of cumulative lead exposure 
on the risk of acquiring T2DM. The study tests the association between cumulative lead 
exposure and T2DM among middle-aged and elderly men. In order to better understand 
the mechanism underlying such an association, an additional stratified analysis is 
conducted with respect to skeletal bone resorption activities.  
Together, the three studies of this dissertation constructed the picture on lead 

































Figure 1.3 Working Interface of Genie 2000 MCA 
Caption: This measurement was taken using Pb phantom at 100PPM. Three lead peaks 
can be observed at energy channel 72.8 keV, 75keV, 85keV. The peak at energy 














Figure 1.4 Scope of the Dissertation 
Caption: The shaded areas represent the lead exposure periods that were of interest in 
the three projects. Chapter 2 studies the effects of lead exposures in utero and in early 
life (birth to early adolescence) on psychobehavioral development. Chapter 3 focuses 
on modifying effect of genetic variants on the effect of cumulative lead exposures in the 
etiology of Parkinson’s disease (PD). Chapter 4 focuses on the effect of cumulative lead 
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2. CHPATER 2 EFFECT OF TIMING OF LEAD EXPOSURE IN EARLY LIFE ON 
CHILDHOOD NEUROBEHAVIORAL OUTCOMES 
Introduction 
Recent epidemiological studies have shown an increasing trend in the 
prevalence of serious emotional and behavioral disorders in early childhood. 1. 
Behavioral disorders are often underreported and they are given less attention 
compared to intelligence problems. The consequences of underestimating the public 
health significance of childhood emotional and behavioral disorders can be serious. In 
the long run, lack of proper management of emotional and behavioral disorders would 
not only aggravate the quality of life of the suffering individuals, but it could also lead to 
public safety concerns. Psychobehavioral development in early life is shaped by the 
child-rearing environment. Nevertheless, behavioral problems cannot be solely 
explained by the factors related to parenting. In recent years, studies on environmental 
chemical exposures from the living environment have shed light on the etiology of 
behavioral problems in childhood 2-4.  
The toxic effects of lead have been well studied. Several cross-sectional studies 
have shown the associations between lead exposures and behavioral problems. 
Studies have linked concurrent blood lead levels to anxiety, social problem5, inattentive 
and hyperactive- impulsive behaviors6, 7, aggression8 as well as attention deficit 
hyperactivity disorder (ADHD)9-14. Lead effects on behavioral problems can be observed 
as early as age of 35 through adolescence15.  
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A handful of studies have explored the timing of lead exposure on long-term 
neurobehavioral outcomes. Current knowledge suggests that the effect of lead 
exposure in the early life could extend to later life15, 16.  For instance, exposure to lead 
between the ages of 12 to 33 months in humans was found to be associated with 
externalizing behaviors and school problems at age of seven17. The Cincinnati lead 
study also found that prenatal lead exposure has the strongest impact on attention 
deficit at the age of 6.5 years compared to the lead exposure in early childhood16. 
Needleman et al18 used K-shell X-ray Fluorescence Spectroscopy to measure and 
explore the relationship between retrospective lead exposure and neurobehavioral 
outcomes at the ages of seven and eleven. They found that children with a higher 
concentration of lead were more likely to be delinquent, aggressive, anxious or 
depressed, and they were more likely to have externalizing and internalizing problems.  
Despite evidence from these studies suggesting a relationship between early life 
lead exposure and behavioral problems, some questions have not yet been explicitly 
addressed in the literature.  First, the current knowledge is primarily based on cross-
sectional studies, that show the association between lead exposure and behavioral 
problems at one time point. This level of evidence is insufficient to establish a causal 
relationship between lead exposure and psycho-behavioral outcomes. It is important to 
address the chronological order of lead exposure in studies in order to gain an in depth 
understanding of the mechanisms of the effect of lead on neurobehavioral development. 
It is of special importance to note that bone lead can serve as an endogenous source of 
lead exposure during rapid skeletal growth in early life19, 20. Therefore, the observed 
lead levels in blood can be a reflection of previous exposures. Ignoring this relationship 
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may result in inaccurate or biased effect estimates at the time-point of interest21, 22. 
Second, even though a handful of longitudinal studies have shown that early life lead 
exposure could have long-term impacts on behavioral development, the effect of the 
timing of lead exposure on behavioral development is not clear and is not well-
discussed in the literature. This study fills this gap in the literature and reports on the 
critical windows of lead exposure in early life by measuring lead exposure during 
gestation, during the first four years of life and during childhood and early adolescence 
and the impact of these lead exposure measurements on neurobehavioral development. 
Specifically, the primary aim of this analysis was to investigate the programming 
influence of exposure to lead in early life and to evaluate the toxic effects of timing of 
lead exposures on the neurobehavioral performance from childhood to early 
adolescence. We hypothesized that increasing levels of lead exposures in early life 
would be associated with an increasing propensity for developing behavioral problems.  
Methods 
Study Design 
This analysis is embedded in the parent birth cohort of Early Life Exposure in 
Mexico to ENvironmental Toxicants (ELEMENT) study23. The study is constituted of 
three mother-infant pair birth cohorts recruited in Mexico City, Mexico starting in 1994, 
1997 and 2001. The overall goal of this study was to explore the associations between 
early life environmental exposures and a cascade of health outcomes in the offspring. 
Upon the completion of the first stage of this study, subjects from three cohorts were 
selected and combined into a cohort of subjects for this study. 204 mother-infant pairs 
from the 1994 cohort, 367 pairs from the 1997 cohort (223 in Biomarker cohort (BI) and 
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144 in Plasma cohort (PL)) and 216 pairs from the 2001 cohort were eligible, yielding a 
total 787 mother-infants pairs for this study.  
Subject Selection 
Subjects were recruited at one of three clinics (Mexican Social Security Institute, 
Manuel Gea Gonzalez Hospital and the National Institute of Perinataology) in Mexico 
City. When pregnant women were screened for initial recruitment into the parent birth-
cohort study, they were excluded if they exhibited any of the following conditions: any 
factor that could interfere with maternal calcium metabolism; reported intention not to 
breastfeed; preeclampsia, kidney or cardiac diseases, gestational diabetes, history of 
urinary infections, family or personal history of kidney stone formation, seizure disorder 
requiring daily medications; ingestion of corticosteroids, or a single-parent household. 
They were later excluded from the study if they were given a physical diagnosis of 
multiple fetuses of if their child had one of these conditions: a gestational age which was 
less than 37 weeks, a birth weight less than 2000g, an infant Apgar score of 6 or under 
at 5 minutes, a condition that required admittance to the NICU or a serious birth defect. 
When reconstituting the current cohort, subjects were preferentially selected based on 
availability of information regarding past exposure, questionnaires, health status and 
demographic characteristics. The study subjects in the current cohort represent low to 
middle-class people in the local region. The behavioral test results vary by age therefore 
created a pronounced cohort difference in the dataset. Additionally, gestational blood 
samples were only available in cohort 2 PL and cohort 3. Therefore, we decided to use 
cohort 2 and cohort 3 in this analysis. As a result, a total of 583 subjects, 223 from 
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cohort 2 BI, 144 from cohort 2 PL, and 216 from cohort 3 were entered into the final 
dataset. 
The research protocol was approved by the Institutional Review Boards (IRB) of 
the National Institute of Public Health of Mexico  (Instituto Nacional de Salud Publica 
(INSP)), the Harvard School of Public Health, the Brigham and Women’s Hospital, the 
University of California, the University of Michigan School of Public Health, and the 
participating hospitals. Written informed consent and/or assent were obtained from all 
participants. 
Lead Exposure Measurements 
Prenatal Lead Exposure  
Prenatal lead exposure was estimated by measuring lead in maternal venous 
blood in cohort 2 PL and cohort 3, in cord blood, and in maternal bone lead. Maternal 
peripheral venous blood samples were collected once during each trimester of 
pregnancy using trace-metal free tubes after sanitizing the lancet site. Umbilical cord 
blood was collected at delivery for lead measurement. Atomic absorption spectrometry 
was used to measure lead in whole blood. 
Maternal bone lead is a proxy for early lead exposure stemming from 
mobilization of maternal bone lead stores.  Although bone lead is not trimester-specific 
and it does not take into account ongoing external exposure, it still can be considered a 
biomarker for early life lead exposure in utero. Between one to 30 days post-partum, 
maternal bone lead levels were measured using K-shell X-ray fluorescence 
spectroscopy at the tibia and the patella.  
 
 34 
Postnatal Lead Exposure  
Postnatal exposure was assessed by collecting offspring blood from peripheral 
veins and fingertip capillaries at 3, 6,12,18,24, 30, 36, 48 months of age. Blood was also 
collected from the children during their neurobehavioral tests. During these 
neurobehavioral tests, the youngest of these children was six years old and the oldest 
was 13. All of the blood samples were collected in trace metal-free tubes after thorough 
sanitation at lancet sites. Blood samples from birth to 48 months were analyzed using 
atomic absorption spectrometry instrument at the Metals Lab of the American British 
Cowdray Hospital in Mexico City. External blinded quality control samples were 
provided throughout the study period by the Maternal and Child Health Bureau of 
Mexico City and by the Wisconsin State Laboratory of Hygiene Cooperative Blood Lead 
Proficiency Testing Program. Precision and accuracy with a correlation coefficient of 
0.99 and a mean difference of 0.17 µg/dL were achieved. Due to the systematic 
difference between fingertip capillary and venous blood measures, only venous blood 
levels were used in this analysis. Blood samples collected during neurobehavioral visits 
were analyzed at University of Michigan and Michigan Department of Community Health 
using the Inductively Coupled Plasma Mass Spectrometry (ICP-MS) method. The 
quality control showed satisfactory accuracy and precision with a detection limit of 1.3 
µg/dL. 
Outcome Measurements  
The psychobehavioral outcomes were scored using the Behavioral Assessment 
System for Children, second edition (BASC-2)24, Conners Rating Scales Revised(CRS-
R) 25, and Conners’ ADHD/DSM-IV Scales Parents (CADS-P)26 completed by both 
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children and parents. These tests were administered by trained examiners who were in-
turn were supervised by psychometricians or psychologists in Mexico City. We chose 
these tests in order to fully capture the effect of lead on psychobehavioral development. 
These tests measure behavior domains of inattention, hyperactivity, internalizing 
problems, externalizing problems, emotional controls, compulsive behavior, social skills 
and adaptive skills. BASC-2 is a coordinated system of psychological assessment that 
evaluates the behavioral and emotional problems in children and adolescents and the 
Self-Reported of Personality (SRP), and Parent Rating Scales (PRS) subscales were 
applied to this study. The BASC-2 questionnaires contained clinical scales and adaptive 
scales covering both adaptive and maladaptive behaviors. There were four composites 
of PRS: externalizing problems, internalizing problems, behavioral symptoms index and 
adaptive skills. Five composites were evaluated on SRP: Clinical Maladjustment 
Composite, Personal Adjustment Composite, Emotional Symptoms Index, and Suicidal 
Risk. Higher scores on clinical scales indicate disruptive or internalizing problems 
whereas lower scores on the adaptive scale indicate lower adaptability, social skills, 
functional communications, leadership skills and study skills. CRS-R was applied to 
parents or caregivers. Scales in CRS-R covered behavioral problems on opposition, 
cognitive problems, inattention, hyperactivity, anxious-shy, perfectionism, social 
problems, psychosomatic, Conners’ Global Index, DSM-IV Symptom Subscales, ADHD 
Index. Conners’ ADHD/DSM-IV Scales Parents (CADS-P) is featured by DSM-IV 
Symptom subscales that distinguishes the inattentive and hyperactive-impulsive 
subtypes of ADHD. All scales were standardized into T-scores. A higher score on CRS-
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R and CADS-P indicates increased tendency to have corresponding behavioral 
problems.  
Measurement of Confounders  
Maternal age, marital status, parental education levels, social economic status of 
family, and maternal smoking behavior during pregnancy was obtained from a 
questionnaire administered to the mothers. Birth weight, which can be consequent from 
prenatal lead exposure 27 is also a risk factor for behavioral problems4, 28, 29 so, this was 
obtained from clinical records. 
Statistical Analyses 
Univariate and Bivariate analyses 
All statistical analyses were performed in R version 2.15.2 30. All significance 
testing was two-sided and was determined at p< 0.05. Univariate analysis was 
performed to examine the distribution of the variables of interest. Extreme observations 
that were at least four standard deviations away from the means were removed from the 
analysis. 
All lead exposure variables were treated as continuous variables. Prenatal lead 
exposure variables included cord blood lead levels, gestational maternal venous blood 
lead levels, and maternal bone lead levels. Maternal blood lead levels during gestation 
were integrated as a cumulative blood lead level (CBLL) calculated using equation 2.1. 
Postnatal lead exposures were divided by three time points: the first and the second two 
years post-delivery and lead exposure at the time of neurobehavioral testing. 
Cumulative blood lead level index at each time point was integrated using blood lead 
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level at each follow up time point using equation 2.1. The strength of the correlation 
coefficients among lead exposure variable pairs were calculated and tested for 
significance.  
1 
The agreement between parental rated scales and children’s self-reported scales 
was assessed with Pearson’s correlation coefficients and was tested for statistical 
significance. All the behavioral assessment scores were treated as continuous 
variables. Maternal marital status, mother’s smoking status during pregnancy and 
child’s sex variables were categorized. Maternal age and educational years, child’s age 
at behavioral tests, socioeconomic status (SES) levels, and birth weight were treated as 
continuous variables. Age, SES level and birth weight were centered for the purpose of 
interpretation.  
Statistical Modeling 
Our analytic strategy consisted of two stages: residual extraction from pair-wise 
lead exposures regression and multivariate regression modeling adjusted for covariates. 
First, in consideration of adjusting for the correlations among lead exposures, residuals 
from each consecutive pair of lead exposure regression model were extracted and 
referred as Xj’ in equation 2.2. This approach is commonly seen in nutritional 
epidemiology for controlling correlated nutrition intake21, 22. The rationale in the 
environmental exposure assessment context is illustrated in the Appendix. Except for 
prenatal lead exposure levels, all other observed blood lead levels were regressed on 
                                            
1 Detailed captions are provided in the Appendix 
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lead exposure in the previous window. In the second stage, all residuals were fitted 
simultaneously into the covariate-adjusted models.  
! 
X j = " j#1X j#1 + X j
' (2.2) 2 
Gestational lead exposures were approximated by maternal blood lead, umbilical 
cord blood lead and maternal bone lead separately. Due to the sample availability, 
gestational blood based modeling was performed in cohorts PL and SF. The original 
intent for models using cord blood lead as prenatal lead exposure indicator was to 
include cohort 2 (BI and PL) as well as cohort 3 in the dataset. But cohort 3 was 
excluded due to tremendous missing data therefore only cord blood lead from cohort 2 
was used. Maternal bone lead models were collected from women in cohorts 2 and 3 
and they were combined. Cohort-specific analyses were also performed as sensitivity 
analyses. In these analyses, prenatal blood lead models were the primary focus. We 
chose not to report the results from the bone lead models as the primary findings due to 
following reasons: maternal bone lead was taken one month post-delivery and evidence 
has shown that bone turnover after delivery is higher than that in pregnancy32. In 
addition, cohort 3 was involved in a calcium supplement randomized trial33 and shown 
to have lower bone lead mobilization during pregnancy. Therefore, post-delivery bone 
lead levels may less accurately reflect fetal exposure levels and could result in biased 
effect estimates due this cohort difference. 
                                            
2 Detailed captions and proof are provided in the Appendix 
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All other biologically relevant confounders were selected into the model at the 
initial step. Multicollinearity diagnosis and F-statistics of model fitting were used for 
covariates selection. Coefficient estimates were standardized as in one standard 
deviation increase in exposure to the amount of change in standard deviation in 
outcomes. Maternal age, years of education, marital status, smoking behavior during 
pregnancy, family SES level, and children’s sex, age and birth weight were included in 
the final models. 
Model diagnosis was performed with regard to linearity assumption, constant 
variance assumption, identifying influential points and collinearity. The penalized spline 
smoothing method was applied for linearity examination. Linearity diagnosis showed 
very limited number of models that followed non-linear relationships (<5%). Therefore, 
multivariate linear regression model was applied to the final models. Homoscedasticity 
was examined by Breusch-Pagan test. Variance inflation factor (VIF) at 1.56, which 
corresponded to r=0.6, was used as collinearity index. Influential points were identified 
by Cook’s distance at 0.5 or larger. Sensitivity analysis was performed to compare 
coefficient estimation upon removal of the influential point(s).  
Results 
A total of 583 subjects entered the final study with different amounts of missing 
information on major variables of interest. The mean ages of children were 9 years in 
cohort 2, and 7 years in cohort 3. Table 2.1 summarizes the exposures and 
psychobehavioral outcomes in the three cohorts. Umbilical cord blood levels were 4.31 
µg/dL, 6.37 µg/dL and 3.22 µg/dL in cohort 2 BI, PL and cohort 3, respectively. 
Cumulative blood lead levels from maternal gestational blood on average were 7.58 
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µg/dL and 4.83 µg/dL in cohort 2 PL and cohort3. Cumulative blood lead levels from the 
first two years exceeded 5 µg/dL in cohorts 2 and 3, and cumulative blood lead levels 
from the second two years were slightly higher than that of the first two years. Weak to 
moderate Pearson’s correlations among lead exposures in different windows were 
found (Figure S 2.2 and Figure S 2.3).  No significant pair-wise correlations were found 
in pair-wise extracted residuals. The distributions of behavioral outcomes are shown in 
Table 2.1. In total there were 23 behavioral scales and all were scored within the normal 
range. ANOVA tests showed significant cohort differences on BASC-2 SRP scales with 
cohort 3 (SF) scoring slightly higher (worse) than cohort 2 (BI and PL). This difference 
was not detected in most of parental rated scales. The concordance between children’s 
self-rated scales and parental rated scales was lower (data not shown). 
In the bivariate analyses, lead exposure did not show significant correlations with 
major behavioral outcomes. Maternal educational level and SES level showed 
significant negative correlations with children’s blood lead levels after birth and with 
behavioral outcomes. Gestational age and birth weight showed significant negative 
correlations with internalizing problems and inattention. Table S 2.1 and Table S 2.2 
showed the comparison of the exposure and outcome characteristics between groups 
with complete and incomplete data in cord blood lead models subjects and in 
gestational blood lead models subjects. The included and excluded groups showed 
comparable lead exposure levels, but were slightly different in some behavioral 
outcomes such as hyperactivity and impulsive behavior. In general, the excluded 
subjects groups scored higher (worse) compared with included subjects.  
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Table 2.2 shows adjusted cord blood lead models. A significant association was 
observed between Perfectionism on CRS-R and cord blood lead at p<0.05. Otherwise, 
cord blood lead was not significantly associated with measured behavioral outcomes. In 
the majority of behavioral outcome models, however, the tendency toward behavioral 
problems increased with elevated cord blood lead. Increases in blood lead levels in the 
first two years post-delivery were generally associated with higher (worse) scores. The 
effect estimates of the first two years exposure tend to be stronger than those of 
exposures in any other exposure windows. Except for Inattention/Hyperactivity on 
BASC-2 self-reported scales, none of the behavioral outcomes showed statistical 
significant associations with blood lead during the first two years. Blood lead in the third 
and fourth years and at the tests (around 9 years in cohort 2) did not show strong 
significant associations with any behavioral outcome.  
Gender differences were observed; females were rated worse by parents on 
attention problem scales, but they were rated better on the Personal Adaptive Skills and 
Internalizing Problem scales on BASC-2 PRS. Higher maternal age, education level and 
SES level were associated with better behavioral outcomes in children.  
In the gestational blood models, no statistical significant associations were found 
between lead exposures and behavioral outcomes (Table 2.3). Blood lead levels at the 
time of the behavioral test (9 years in cohort 2 PL and 7 years in cohort 3) were 
negatively associated with the Psychosomatic scale on CRS-R. On the other hand, the 
magnitude of effects of lead exposure during the gestational period and in the first two 
years post-delivery tend to be greater on inattention and hyperactivity scales (e.g. 
Inattention/Hyperactivity on BASC-2 SRP, Cognitive Problems/Inattention, Global 
 
 42 
Restless-Impulsive Index, and ADHD Index on CRS-R, Hyperactive-Impulsive, 
Inattention on CADS). In addition to the concordant observations on the effects of 
children’s sex, maternal age and educational levels, the results in gestational blood 
models showed that an increase in birth weight was associated with better behavioral 
outcomes. Cigarette smoking during pregnancy was significantly associated with worse 
outcomes related to Externalizing Problems, Opposition and to the Behavioral Symptom 
Index.  
In maternal bone lead models, maternal bone lead levels in tibia and patella 
showed significant protective effect on inattention, impulsive behaviors. None of the 
lead exposures in other windows were significantly associated with behavioral 
outcomes (data not shown).  
Discussion 
In these analyses, we did not find statistically significant evidence of any 
deleterious effects of early lead exposure on psychosocial status of children aged 6 to 
13 years. When weighing the direction and magnitude of lead effects among the early 
life exposure windows, however, the data suggests that lead exposures in the prenatal 
period and in the first two years after birth has a greater impact on behavioral outcomes 
like inattentive and hyperactive behaviors between the ages of 6 and 13 years. The 
results also suggest that lead exposure in these windows could affect control of 
emotions and somatic perception development in children. Compared to perinatal lead 
exposure, lead exposure later in life showed a weaker impact on children’s behavioral 
development. Our results suggest that lead exposure during the first two years after of 
life is a critical window of exposure as it shows a strong and long lasting impact on 
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behavioral development. It also suggests that the effect of prenatal lead exposure was 
mediated via secondary endogenous lead exposure from maternal bone lead released 
during active bone turnover in pregnancy. Consistent with current knowledge on the 
deterministic factors on behavioral development, we found that parental factors that 
may indicate a good child-rearing environment such as higher maternal educational 
levels and social economic status34 are associated with better outcomes on 
psychosocial behavioral development. In addition, low birth weight showed strong 
association with inattention and hyperactivity behaviors in gestational blood lead 
models. 
Unlike findings from studies with a cross-sectional study design, our results 
indicate that concurrent lead exposure was not the major contributor to the behavioral 
problems during the childhood-early adolescence period, but exposure during the first 
two years of life had a greater impact These results could be attributed to the more 
detailed and refined analysis in this longitudinal study; we fitted lead exposures from all 
exposure windows simultaneously and adjusted for inter-correlations using the residual 
method. This has two implications for lead effect estimates. First, the pair-wise residual 
method solved the correlation issue among lead exposures, and it modeled the 
endogenous lead circulation between bone and blood during the rapid skeleton growth 
in the early life. Therefore, the observed blood lead levels reflected both historical and 
current lead exposures. Second, fitting lead exposure variables simultaneously 
constrained the potential mediating effect from earlier exposures that can be reflected 
by the current exposure. The detailed proof is provided in the appendix. This method, 
compared to the models fitting lead exposure at each window separately, increased the 
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magnitude of the effect estimates. The effect estimates, however, from this method did 
not differ greatly in terms of the directions and the magnitude of effects compared to the 
models fitting observed lead levels simultaneously (result not shown). Yet, in several 
models the residual method slightly improved efficiency than the models that did not 
adjust correlations among exposures (results not shown). The other explanation for the 
weak impact from blood lead measured at the time of the behavioral tests is that the 
levels of exposure were low (<5 µg/dL on average in all cohorts). It is possible that the 
amount of lead reaching the brain is even lower given that most of children may have 
developed protective mechanisms from lead intoxication in the central nervous system 
at the age of 5 or older 35. Therefore, the lead can hardly exhibit strong effects with this 
low exposure range.  
Our study result is compatible with the findings from the Cincinnati lead study16. 
In this study, the researchers examined effects of lead exposure using prenatal 
maternal blood lead, children’s blood lead averaged from first five years and at 78 
months on cognitive, behavioral and motor functions at age15 to 17 years. The 20th and 
70th percentile of the average five-year blood level distribution was 15 µg/dL and 25 
µg/dL, respectively. They found that 78-month blood lead was related to attention 
problems. However, the effect of lead on attention and visuoconstruction functions 
tended to be the strongest in the prenatal period compared to lead exposure in other 
age periods. We examined psychobehavioral functions in children in our study at 
younger ages (6- 13 years) than the Cincinnati cohort. The 20th and 70th percentile of 
the first four years cumulative blood lead levels were 14.4 µg/dL, 23.45 µg/dL in cohort 
2 and 12.72 µg/dL, 22.79 µg/dL in cohorts 2 PL and 3 combined. Our analyses explored 
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the critical windows of lead exposures in shorter time intervals. Our results indicated 
that the exposure to lead in prenatal period as well as the first two years post-delivery 
could contribute to the risk of having attention problems, hyperactivities, and compulsive 
behaviors in children aged 6 to 13 years. However, other behavioral problems such as 
internalizing problems, externalizing problems and school problems were not under 
strong influence of lead exposures in these periods. Our findings on the critical 
exposure windows were inconsistent with current knowledge on the brain structure and 
behavioral development36-38.  
Timing of Psychobehavioral Development 
In humans, the neuronal infrastructure development mainly occurs during the 
prenatal period, while the neuronal reorganization and functional gains occur rapidly 
after birth and reach to full maturation in early adulthood 39, 40. Psychosocial 
development can be traced as far back as the first three years of life. Newborns, in the 
first few hours of life, start to look for simple face-like patterns and this may suggest that 
they are attempting to establish a bond with adult caregivers 37. The major psychosocial 
development in infants involves the limbic nuclei, and it is mainly through the 
‘experience-expectant’ mechanism. Experience-dependent plasticity is a type of 
behavior-learning approach whereby infants gain functions and develop psychosocial 
affections through their interactions with the child-rearing environment. This plays a 
crucial role in the psychosocial development in the first few years of life, so, it could play 
a role in behavioral problems in adulthood3. If deprived of environmental stimuli, infants 
exhibit various degrees of functional deficits with the severest damage being 
permanent. For instance, infants who were separated from the caregiver (e.g. mother) 
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repeatedly or for a long period in the first three years of life, exhibit social withdrawal, 
pathological shyness, aggressive and inappropriate emotionality and they are incapable 
of forming normal emotional attachment 41, 42. Depending on the window that stimuli 
deprivation occurred, children manifest dissimilar subtypes of behavior problems which 
reflects different brain regions that were affected 3. Our results also show that the child-
rearing environment plays a crucial role in children’s psychobehavioral development. 
Higher maternal age and educational levels and social economic status level implies 
better capabilities in supporting and promoting the physical, emotional, social, and 
intellectual development of a child. These variables were shown to reduce the 
probability of developing negative behavioral problems.  
Intrinsic and Extrinsic Factors Affecting Biosocial Development  
Both intrinsic and extrinsic environments are involved in guiding the development 
of psychosocial behaviors. For example, dopamine is one of the most important 
neurotransmitters that is highly involved in reward learning and it is associated with 
neuronal branching and outgrowth43, 44. Sex is a major determinant of patterns of 
neurobehavioral development. During the peri-adolescent period, dopamine receptor 2 
in males is overproduced and is subsequently eliminated by around 40%. However this 
fluctuation is not observed in females40 . Females in general reach grey matter and 
white matter peaks, which mark the brain maturation, ahead of males. Yet regional 
differences have been observed between sexes. It is observed that during adolescent 
period amygdala volume bumped up greatly in males, whereas right hippocampus 
volume increases in females 40.  
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The extrinsic environment has a strong and direct impact on behavior 
development. In this study, we found the suggestive effects of lead exposure during the 
prenatal period and during the first two years after birth to be the strongest on 
inattentive and hyperactive behaviors. This can be explained with two possible 
biological mechanisms. First, the fetal brain lacks protective mechanisms to defend 
against lead poisoning. Studies show that adult endothelial cells in the blood brain 
barrier have a lower permeability to lead, and mature astroglias are capable of pumping 
lead back into blood stream against a concentration gradient 45-47. Without a fully 
developed blood brain barrier structure, neurons and glias are directly exposed to lead 
transported from the blood. This explains why this window is particularly vulnerable to a 
low concentration of lead from the circulation and why pronounced neuronal 
impairments can be observed 48. Previous studies confirm that the developing brain is a 
target organ for lead poisoning 48, 49. In rat studies, animals chronically exposed to lead 
sequestered lead in zinc rich regions like the hippocampus 50, while animals with acute 
exposure showed more lead, in the pons medulla, cerebellum, midbrain and cortex 
striatum 49. Second, as previously mentioned, the limbic system which is involved in 
emotional memory and socialization, develops and matures quickly in the first three 
years of life 51. Our evidence suggests that the damage occurred during this 
neurodevelopment period cannot be reversed and the functional deficits can be long-
lasting.  
Furthermore, our findings shows that birth weight is a strong factor in predicting 
inattention and hyperactivity problems at age 6 to 13. This again suggests that the 
perturbation occurred in early life, especially during the gestational period could result in 
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permanent behavioral deficits. Obstetric complications, such as anoxia, forceps 
delivery, pre-eclampsia can result in brain damage that is related to psycho-behavioral 
development 52. Our data also suggests that maternal smoking behavior is related to 
increased tendency on externalizing problems, opposition, atypicality and withdrawal 
behaviors. Smoking behavior in pregnant women would expose the fetuses not only to 
nicotine, but also to carbon monoxide. Nicotine exposure during the prenatal period 
interferes with the development process in the cerebral cortex, and the early 
disturbance from smoking exposure has a long-term impact on behavioral development. 
Offspring who had been exposed to maternal smoking during pregnancy are twofold 
likely to have a criminal record than negative controls, even after adjusting for socio-
economic status, childrearing behavior, parenting behavior and birth complications 52. 
However, neurodevelopment is constantly shaped by the interactions between intrinsic 
cues and the extrinsic environment. When accounting for criminality and antisocial 
personalities of the parents, the magnitude of the association attenuated. Yet, the 
smoking effect was stronger in subjects who were born with complications, born to 
teenage mothers, born into single parent families, or showed motor development lags.  
We believe that our approach, compared to others, resulted in comparisons that 
were more reliable, and it builds validity by testing on multiple behavioral scales and by 
covering diverse behavior domains. Even though most of the literature favors parental 
rated results to self-reported results in young children, our result shows good validity of 
children’s responses. The responses from BASC-2 SRP were more sensitive for 
detecting age effect in response to lead exposure. Our data showed that BASC-2 SRP 
captured the cohort difference introduced mainly by age (average 9 in cohort 2 and 7 in 
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cohort 3), while parental rating scales did not detect this feature. Furthermore, even 
though the results were all non-significant, the magnitudes of the lead effects were 
stronger in children’s self-rated scales than in parent-rated scales. A discrepancy in 
gender effects between SRP and PRS was observed; females tended to rate 
themselves better than males while parents rated females worse on inattention and 
hyperactivity scales. Parental rating is contradictory to the current knowledge that 
ADHD is more prevalent in males53. However, our results show that the consistency of 
lead effects on overall behavior problems disregard responders. Therefore, we believe 
the results are valid.  
On the other hand, these results should be placed in the appropriate context. 
First, this study was conducted in the low-middle class Mexican population so, the lead 
effects cannot be directly applied to other ethnic populations or social classes. 
Moreover, sensitivity analysis showed cohort specific patterns of the effects of lead. We 
observed strong and significant effects of gestational blood and first-two-year blood lead 
on inattention/ hyperactivity scales in cohort 2 PL, while in cord blood lead models using 
cohort 2 PL, blood lead in the first two years showed a strong and significant detrimental 
impact on ADHD related scales. Cohort 2 BI showed that the first two years blood lead 
have the strongest and significant influence on personal adjustment and perfectionism, 
but they have a weak impact on ADHD-like behavior scales. Given these findings, 
results from combined cohort analyses should be cautiously interpreted due to the 
diverse responses in the sub-populations. Secondly, neurobehavioral measurement 
was examined at one time. We do not have data to show the behavioral changes 
overtime as a function of early lead exposures. Hormonal levels also change in 
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adolescent period and it is another important factor affecting behavioral formation.  It 
would definitely provide new understanding on the effect of timing of lead exposure on 
psychobehavioral development as a dynamic growing process. Third, excluded subjects 
can also impact the effects estimates. A comparison of groups with and without 
complete information showed the similar distributions in lead exposure, but not in 
several behavioral outcomes. Slightly worse scores were observed on inattention scales 
in the excluded group. This may indicate a minor differential missing issue so that our 
models only captured subjects with slightly better behavioral outcomes, and it could be 
that the excluded group can be more vulnerable to lead or less likely to follow protocol 
due to attention problems. Therefore, the lead effect estimates could be deflated based 
on complete observations. 
In conclusion, this is the first analysis comparing the effects of lead exposure at 
different windows in early life on neurobehavioral outcomes. Unlike previous findings on 
concurrent lead effects on these outcomes, our data implied that lead exposure during 
the gestational period and the first two years after birth have strong and long-lasting 
impacts on behavioral problems in childhood or early adolescence. The main effect of 
lead implicated a deleterious effect on behavioral development, but child-rearing 
environment factors such as mother’s education, SES levels had even greater impact 
on a child’s psychobehavioral development. Future studies may need to clarify the 
effects of the temporal exposure patterns on a large scale, as well as to provide a new 
understanding of the effect of timing of lead exposures on psychobehavioral 






Table 2.1 Characteristics of Study Participants by Cohorts 
  BI  PL  SF 3   
  N Mean SD N Mean SD N Mean SD  
Maternal Blood Pb 1st Trimester (µg/dL) 0 - - 120 7.58 3.51 213 4.83 3.14 **4 
Maternal Blood Pb 2nd Trimester (µg/dL) 0 - - 134 6.89 3.32 211 3.88 2.72 ** 
Maternal Blood Pb 3rd Trimester (µg/dL) 0 - - 121 7.15 3.49 203 4.61 2.95 ** 
Gestational Blood Pb Level (µg/dL)5 0 - - 101 4.43 1.77 197 2.81 1.64 ** 
Patella Pb (µg/g) 221 8.93 9.88 109 13.68 11.23 182 7.05 9.02 ** 
Tibia Pb (µg/g) 212 8.7 10.05 96 11.62 9.51 88 5.04 8.21 ** 
Cord Blood Pb (µg/dL) 170 4.31 2.52 73 6.37 4.16 38 3.32 2.54 ** 
Children Blood Pb Level 1-2year (µg/dL) 222 8.54 5.1 141 10.21 6.01 209 9.14 5.73 ** 
Children Blood Pb Level 3-4year (µg/dL) 220 11.36 4.27 143 12.85 5.81 177 9.75 4.37 ** 
Children Blood Pb Level 4years (µg/dL) 223 20.04 8.08 143 23.34 10.26 215 18.85 9.77 ** 
Children Blood Pb Level at tests (µg/dL) 167 3.13 3.09 109 3.21 2.13 138 3.75 3.1   
BASC SRP: School Problems 223 51.57 10.25 138 51.2 9.8 50 53.3 10.32 * 
BASC SRP: Internalizing Problems 222 50.27 7.88 138 50.93 7.88 50 55.54 10.4 ** 
BASC SRP: Inattention/Hyperactivity 223 52.94 10.23 138 53.31 10.46 50 56.7 11.38   
BASC SRP: Emotional Symptoms Index 223 50.72 8.29 138 51.3 8.28 50 55.72 9.52 ** 
BASC SRP: Personal Adjustment 222 48.55 8.21 138 47.72 9.27 50 43.88 9 ** 
BASC PRS: Externalizing Problems 217 49.8 9.45 136 50.84 9.72 211 48.03 9.35 * 
BASC PRS: Internalizing Problems 217 53.4 10.77 136 52.88 10.08 211 51.47 9.68   
BASC PRS: Behavioral Symptoms Index 216 51.34 9.61 137 51.37 10.43 210 49.98 8.9   
BASC PRS: Adaptive Scale 217 46.43 10.11 137 47.79 10.41 212 47.02 10.22   
CRS-R: Opposition 217 51.01 8.23 136 50.55 9.69 211 50.04 9.31   
CRS-R Cognitive Problems/ Inattention 217 54.49 10.32 137 54.35 11.32 212 53.52 10.48 * 
CRS-R: Hyperactivity 217 56.05 11.23 137 56.35 12.18 212 54.55 9.03   
CRS-R:  Anxious- Shy 217 57.17 11.59 137 56.2 10.26 212 54.45 10.68 * 
CRS-R: Perfectionism 217 51.89 8.07 136 52.01 7.98 211 51.64 7.65   
CRS-R: Social Problems 216 53.47 10.26 137 52.64 10.2 212 53.6 10.79   
CRS-R: Psychosomatic 217 54.03 11.72 137 54.04 11.13 210 52.84 9.94   
CRS-R: ADHD Index 216 54.69 10.72 137 54.35 11.17 212 53.45 9.84   
CRS-R: CGI Restless-Impulsive 217 54.68 9.87 137 55.55 11.5 212 53.75 9.89   
CRS-R: CGI Emotional Lability 215 50.47 8.61 137 51.71 10.69 212 49.42 8.61   
CADS: DSM IV Inattentive 217 53.62 9.93 137 53.66 11.67 212 52.97 9.66   
                                            
3 Cohort BI, PL constitute cohort 2. Cohort 3 is labeled as cohort SF. 
4 *p<0.05, ** p<0.01 from either Fisher’s exact tests or ANOVA tests 




CADS: DSM IV Hyperactive-Impulsive 217 57.58 10.77 137 57.94 11.65 212 56.08 9.91   
CADS: DSM IV Total 217 55.85 10.41 137 56.11 11.23 212 54.67 9.73   
Maternal Age 223 24.92 5 144 26.68 5.25 216 26.81 5.74 ** 
Years of Education (Maternal) 223 10.92 2.75 144 10.62 2.86 216 10.99 2.9 ** 
Years of Education (Paternal) 205 10.9 3.16 144 9.95 4.31 190 10.81 2.94 ** 
Social Economic Levels 216 8.75 3.12 137 9.07 3.46 204 8.49 3.21 * 
Ever Smoked during Pregnancy [N (%)] 222 16 - 144 7 - 216 1 -   
Birth Weight 223 3.17 0.47 141 3.11 0.48 216 3.17 0.51   
Birth Height 223 49.87 2.29 143 49.53 2.71 210 50.18 2.23 ** 
Gestation Length 223 39.05 1.05 140 38.66 1.63 213 38.75 1.41 ** 























Table 2.2 Lead Effects from Cord Blood Lead Models in Cohort 26 
 Cord Blood Lead Blood Lead in the  1st Two Years 
Blood Lead in the  
2nd Two Years Blood Lead at Test 
Models Std.Coeff Std.SE   Std.Coeff Std.SE   Std.Coeff Std.SE   Std.Coeff Std.SE   
BASC SRP: Inattention/ Hyperactivity 0.06 0.08   0.04 0.09   0.18 0.08 * -0.02 0.08   
CRS-R: Cognitive Problems/ Inattention -0.09 0.08   0.07 0.09   0.02 0.09   -0.06 0.08   
CADS: DSM IV Inattentive -0.07 0.08   0.06 0.09   -0.04 0.09   -0.06 0.08   
CRS-R: Hyperactivity -0.02 0.08   0.12 0.09   0.03 0.09   0.02 0.09   
CRS-R: CGI Restless-Impulsive Index 0.01 0.08   0.07 0.09   0.07 0.09   0.04 0.08   
CADS: DSM IV Hyperactive-Impulsive 0.01 0.08   0.11 0.09   0.00 0.09   0.05 0.09   
CRS-R: ADHD Index -0.08 0.08   0.11 0.09   0.05 0.09   -0.02 0.09   
CADS: Total -0.04 0.08   0.11 0.09   0.01 0.09   -0.02 0.09   
BASC SRP: Emotion Symptoms Index 0.13 0.08   0.03 0.09   0.02 0.09   0.04 0.08   
BASC SRP: Personal Adjustment 0.07 0.08   0.03 0.09   0.04 0.09   0.04 0.09   
BASC PRS: Adaptive Scale 0.06 0.08   0.07 0.08   0.10 0.08   0.05 0.08   
CRS-R: Anxious-Shy -0.12 0.08   0.06 0.09   -0.10 0.09   0.02 0.09   
CRS-R: Social Problems 0.00 0.08   0.14 0.09   0.06 0.09   -0.02 0.09   
BASC SRP: School Problems -0.01 0.08   -0.01 0.09   -0.01 0.09   0.07 0.09   
BASC PRS: Behavioral Symptom Index 0.07 0.08   0.13 0.09   0.03 0.08   0.01 0.08   
CRS-R: Psychosomatic -0.06 0.08   0.11 0.09   0.11 0.09   -0.15 0.09 . 
CRS-R: CGI Emotion Lability 0.12 0.08   0.10 0.09   0.06 0.09   0.04 0.09   
BASC SRP: Internalizing Problems 0.13 0.08   0.02 0.09   -0.02 0.09   0.00 0.08   
BASC PRS: Internalizing Problems 0.07 0.09   0.11 0.09   -0.07 0.09   0.01 0.09   
BASC PRS: Externalizing Problems 0.04 0.08   0.03 0.09   0.04 0.09   0.02 0.08   
CRS-R: Opposition 0.03 0.08   0.11 0.09   0.10 0.09   -0.01 0.09   
CRS-R: Perfectionism 0.17 0.08 *7 0.09 0.09   -0.12 0.09   -0.06 0.08   
 
 
                                            
6 All models adjusted for maternal age, educational level, marital status, smoking behavior during pregnancy, socioeconomic status levels, 
children’s sex, age and birth weight. 




Table 2.3 Lead Effects from Gestational Blood Lead Models in cohorts PL and SF8 
 Gestational Blood Lead Blood Lead in the 1st Two Years 
Blood Lead in the 
2nd Two years Blood Lead at the Test 
Models Std.Coeff Std.SE   Std.Coeff Std.SE   Std.Coeff Std.SE  Std.Coeff Std.SE   
BASC SRP: Inattention/ Hyperactivity 0.05 0.13   0.14 0.13   0.06 0.12   0.13 0.13   
CRS-R: Cognitive Problems/ Inattention 0.03 0.10   0.06 0.10   -0.15 0.10   -0.05 0.10   
CADS: DSM IV Inattentive -0.01 0.10   0.06 0.10   -0.16 0.10   0.00 0.10   
CRS-R: Hyperactivity 0.15 0.11   0.13 0.10   0.08 0.10   0.06 0.10   
CRS-R: CGI Restless-Impulsive Index 0.10 0.10   0.12 0.10   0.04 0.10   0.02 0.10   
CADS: DSM IV Hyperactive-Impulsive 0.15 0.11   0.07 0.10   0.07 0.10   0.04 0.10   
CRS-R: ADHD Index 0.07 0.10   0.12 0.10   -0.08 0.10   -0.05 0.10   
CADS: Total 0.07 0.10   0.07 0.10   -0.07 0.10   0.01 0.10   
BASC SRP: Emotion Symptoms Index 0.15 0.13   0.17 0.13   0.02 0.12   0.18 0.13   
BASC SRP: Personal Adjustment 0.00 0.13   0.15 0.13   -0.05 0.12   0.10 0.13   
BASC PRS: Adaptive Scale 0.01 0.11   -0.07 0.10   -0.06 0.10   0.09 0.10   
CRS-R: Anxious-Shy 0.03 0.11   0.11 0.10   -0.01 0.10   -0.11 0.10   
CRS-R: Social Problems 0.03 0.11   -0.08 0.10   0.05 0.10   -0.12 0.10   
BASC SRP: School Problems 0.00 0.13   0.16 0.14   -0.11 0.13   0.02 0.14   
BASC PRS: Behavioral Symptom Index 0.06 0.11   -0.06 0.10   0.01 0.10   0.06 0.10   
CRS-R: Psychosomatic 0.11 0.10   -0.11 0.10   -0.15 0.10   -0.18 0.10 . 
CRS-R: CGI Emotion Lability 0.02 0.11   -0.02 0.10   0.08 0.10   0.08 0.10   
BASC SRP: Internalizing Problems 0.10 0.12   0.14 0.13   0.03 0.12   0.17 0.13   
BASC PRS: Internalizing Problems 0.02 0.11   -0.17 0.10   -0.07 0.10   -0.06 0.10   
BASC PRS: Externalizing Problems 0.06 0.11   0.04 0.10   0.07 0.10   0.16 0.10   
CRS-R: Opposition -0.03 0.11   -0.03 0.10   0.06 0.10   0.04 0.10   
CRS-R: Perfectionism 0.04 0.11   0.01 0.10   -0.11 0.10   -0.02 0.10   
                                            
8 All models adjusted for maternal age, educational level, marital status, smoking behavior during pregnancy, socioeconomic status levels, 




Table S 2.1 Comparison between Included and Excluded Subjects in Cohort 2  
 Pooled Included Excluded  
 N Mean SD N Mean SD N Mean SD 9 
Maternal Blood Pb 1st Trimester (µg/dL) 120 7.58 3.51 41 7.48 3.16 79 7.63 3.69  
Maternal Blood Pb 2nd Trimester (µg/dL) 134 6.89 3.32 50 6.56 3.44 84 7.09 3.25  
Maternal Blood Pb 3rd Trimester (µg/dL) 121 7.15 3.49 48 7.27 3.22 73 7.08 3.68  
Cumulative Gestational Blood Pb Level (µg/dL) 101 4.43 1.77 38 4.31 1.56 63 4.51 1.89  
Patella Pb (µg/g) 330 10.50 10.57 160 11.11 10.22 170 9.93 10.89  
Tibia Pb (µg/g) 308 9.61 9.96 150 9.83 10.17 158 9.41 9.79  
Cord Blood Pb (µg/dL) 243 4.93 3.24 170 4.99 3.28 73 4.80 3.16  
Children Blood Pb Level 1-2year (µg/dL) 363 9.19 5.52 170 9.01 5.27 193 9.35 5.74  
Children Blood Pb Level 3-4year (µg/dL) 363 11.95 4.98 170 12.06 4.73 193 11.85 5.21  
Children Blood Pb Level 4years (µg/dL) 366 21.33 9.13 170 21.23 8.24 196 21.42 9.85  
Children Blood Pb Level at tests (µg/dL) 276 3.16 2.75 170 2.97 2.07 106 3.48 3.56 . 
BASC SRP: School Problems 361 51.43 10.07 170 51.09 9.72 191 51.72 10.39  
BASC SRP: Internalizing Problems 360 50.52 7.88 170 50.09 8.17 190 50.91 7.61  
BASC SRP: Inattention/Hyperactivity 361 53.08 10.31 170 52.75 10.85 191 53.38 9.82  
BASC SRP: Emotional Symptoms Index 361 50.94 8.28 170 50.72 8.36 191 51.14 8.23  
BASC SRP: Personal Adjustment 360 48.23 8.63 170 48.81 8.48 190 47.72 8.75  
BASC PRS: Externalizing Problems 353 50.20 9.55 167 49.44 9.21 186 50.89 9.83 . 
BASC PRS: Internalizing Problems 353 53.20 10.50 166 52.36 10.55 187 53.94 10.43 . 
BASC PRS: Behavioral Symptoms Index 353 51.35 9.92 167 50.22 9.56 186 52.38 10.15 * 
BASC PRS: Adaptive Scale 354 46.96 10.24 167 47.49 10.08 187 46.49 10.38  
CRS-R: Opposition 353 50.84 8.81 168 50.51 8.65 185 51.14 8.97  
CRS-R:  Cognitive Problems/Inattention 354 54.44 10.70 168 53.61 10.11 186 55.18 11.19 . 
CRS-R: Hyperactivity 354 56.17 11.59 168 55.88 11.47 186 56.42 11.72  
CRS-R: Anxious- Shy 354 56.80 11.09 168 55.73 10.91 186 57.76 11.20 * 
CRS-R: Perfectionism 353 51.93 8.03 167 51.65 8.08 186 52.19 7.99  
CRS-R: Social Problems 353 53.14 10.23 167 53.60 10.27 186 52.74 10.21  
CRS-R: Psychosomatic 354 54.03 11.48 168 53.38 11.73 186 54.63 11.24  
CRS-R: ADHD Index 353 54.56 10.88 168 54.44 11.01 185 54.66 10.79  
CRS-R: Restless-Impulsive 354 55.01 10.53 168 55.58 11.08 186 54.51 10.01  
CRS-R: Emotional Lability 352 50.95 9.48 166 50.34 9.07 186 51.51 9.81  
CADS: DSM IV Inattention 354 53.64 10.62 168 52.46 10.02 186 54.70 11.05 * 
CADS: DSM IV Hyperactive-Impulsive 354 57.72 11.10 168 57.30 10.81 186 58.10 11.37  
CADS: DSM IV Total 354 55.95 10.72 168 55.07 10.34 186 56.75 11.01 . 
Maternal Age 367 25.61 5.16 170 25.79 4.84 197 25.46 5.44  
Years of Education (Maternal) 367 10.81 2.79 170 10.92 2.90 197 10.71 2.70  
Years of Education (Paternal) 349 10.51 3.71 164 10.74 3.65 185 10.30 3.75  
Social Economic Levels 353 8.87 3.26 170 8.91 3.16 183 8.84 3.36  
Ever Smoked during Pregnancy [N (%)] 366 13 - 170 15 - 196 11 -  
Birth Weight 364 3.15 0.47 170 3.14 0.43 194 3.15 0.51  
Birth Height 366 49.74 2.46 170 49.96 2.23 196 49.55 2.64  
Gestation Length 363 38.90 1.31 169 39.05 1.12 194 38.77 1.45  
Children’s Age 365 9.41 0.88 169 9.46 0.82 196 9.38 0.93  
 
 
                                            
9 * p<0.05 , . p<0.1 by Student’s t-test between the included and excluded groups 
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Table S 2.2 Comparison between Included and Excluded Subjects in Cohort 2 PL 
and Cohort 3 Combined 
 Pooled  Included  Excluded  
 N Mean SD N Mean SD N Mean SD 10 
Maternal Blood Pb 1st Trimester (µg/dL) 333 5.82 3.53 158 5.83 3.59 175 5.82 3.48  
Maternal Blood Pb 2nd Trimester (µg/dL) 345 5.05 3.31 159 5.05 3.46 186 5.05 3.18  
Maternal Blood Pb 3rd Trimester (µg/dL) 324 5.56 3.39 145 5.67 3.47 179 5.47 3.33  
Cumulative Gestational Blood Pb Level (µg/dL) 298 3.36 1.85 134 3.37 1.88 164 3.35 1.83  
Patella Pb (µg/g) 291 9.53 10.39 129 9.53 10.87 162 9.54 10.03  
Tibia Pb (µg/g) 184 8.47 9.48 82 9.72 9.83 102 7.48 9.12  
Cord Blood Pb (µg/dL) 111 5.33 3.95 50 4.82 3.28 61 5.74 4.41  
Children Blood Pb Level 1-2year (µg/dL) 350 9.57 5.86 163 9.27 5.23 187 9.84 6.36  
Children Blood Pb Level 3-4year (µg/dL) 320 11.14 5.29 150 11.21 5.44 170 11.07 5.17  
Children Blood Pb Level 4years (µg/dL) 358 20.65 10.20 168 21.06 10.99 190 20.28 9.46  
Children Blood Pb Level at tests (µg/dL) 247 3.51 2.73 118 3.49 2.40 129 3.53 3.00  
BASC SRP: School Problems 188 51.76 9.96 87 52.17 10.55 101 51.41 9.46  
BASC SRP: Internalizing Problems 188 52.16 8.83 87 52.17 9.45 101 52.15 8.32  
BASC SRP: Inattention/Hyperactivity 188 54.21 10.79 87 53.97 11.42 101 54.43 10.26  
BASC SRP: Emotional Symptoms Index 188 52.47 8.82 87 52.29 9.36 101 52.63 8.37  
BASC SRP: Personal Adjustment 188 46.70 9.33 87 46.61 10.03 101 46.77 8.74  
BASC PRS: Externalizing Problems 347 49.13 9.58 161 48.83 9.88 186 49.39 9.33  
BASC PRS: Internalizing Problems 347 52.02 9.85 161 52.07 10.05 186 51.98 9.69  
BASC PRS: Behavioral Symptoms Index 347 50.53 9.54 161 50.14 9.23 186 50.87 9.82  
BASC PRS: Adaptive Scale 349 47.32 10.29 161 47.19 10.42 188 47.44 10.20  
CRS-R: Opposition 347 50.24 9.45 160 49.20 9.01 187 51.13 9.75 * 
CRS-R: Cognitive Problems/Inattention 349 53.85 10.81 162 54.02 11.24 187 53.70 10.45  
CRS-R: Hyperactivity 349 55.26 10.40 162 54.20 9.92 187 56.17 10.74 * 
CRS-R: Anxious- Shy 349 55.14 10.54 162 55.10 10.93 187 55.18 10.22  
CRS-R: Perfectionism 347 51.79 7.77 162 52.05 7.85 185 51.56 7.72  
CRS-R: Social Problems 349 53.22 10.56 162 52.38 9.03 187 53.95 11.70 . 
CRS-R: Psychosomatic 347 53.31 10.43 160 52.45 10.07 187 54.05 10.69 . 
CRS-R: ADHD Index 349 53.81 10.38 162 53.50 10.88 187 54.07 9.94  
CRS-R: Restless-Impulsive 349 54.46 10.57 162 53.60 10.68 187 55.20 10.45 . 
CRS-R: Emotional Lability 349 50.32 9.53 162 49.89 9.43 187 50.70 9.62  
CADS: DSM IV Inattention 349 53.24 10.48 162 53.23 10.81 187 53.25 10.22  
CADS: DSM IV Hyperactive-Impulsive 349 56.81 10.65 162 55.70 10.46 187 57.77 10.74 * 
CADS: DSM IV Total 349 55.23 10.35 162 54.80 10.57 187 55.61 10.17  
Maternal Age 360 26.76 5.54 168 27.09 5.46 192 26.47 5.61  
Years of Education (Maternal) 360 10.84 2.88 168 10.90 2.88 192 10.79 2.89  
Years of Education (Paternal) 334 10.44 3.62 158 10.35 3.99 176 10.52 3.26  
Social Economic Levels 341 8.72 3.32 158 8.87 3.44 183 8.60 3.22  
Ever Smoked during Pregnancy [N (%)] 360 3 - 168 2  192 5 -  
Birth Weight 357 3.15 0.50 167 3.15 0.52 190 3.14 0.48  
Birth Height 353 49.92 2.45 165 49.93 2.40 188 49.91 2.51  
Gestation Length 353 38.71 1.50 164 38.74 1.56 189 38.69 1.44  
Children’s Age 338 8.27 1.43 154 8.32 1.46 184 8.23 1.40  
                                            



















Caption: j- observation time; Pbj - observed lead level at time j; t- time interval between j and j+1 
Equation 2.2 
 
Caption: j- observation time points j!1; Xj- observed lead level; Xj’- unobserved additional lead exposure 
The observed blood lead consists both historical and current lead exposures. 
The effect estimates of observed current blood lead level can be confounded by 
chronologically remote exposures. We used the residual method to differentiate the 
effect from additional lead exposures in the current windows. The residuals serve as 
latent exposure variables at each post-delivery window that could not be directly 
observed. Specifically, the current lead exposure can be decomposed as a summation 
of previous exposure and current exposures as expressed in equation 2.2. This is 
biologically relevant to the lead mobilization from bone to blood during active bone 
turnover period, such as rapid skeletal growth. In equation 2.2, Xj and Xj-1 denote 
observed lead levels; "j-1 characterized the fraction of current blood lead that can be 
explained by previous blood lead. Xj’ indicates the additional blood lead that cannot be 




blood lead from previous lead exposure is fixed and indicated by "j-1 for every individual, 
while the additional exposure (Xj’) in current window varies across individuals.  
When fitting regression models with observed lead levels separately, the 
previous exposures have been counted due to the intercorrelations among exposures, 
as illustrated in Equation 2.3. 
Equation 2.3 
 
Caption: k- observation windows, k= 1,2#j-1; j- observation time points j!1; Xj- observed lead level; Xj’- 
unobserved additional lead exposure; Y- the outcome measured at or after the window max(j); $j- effect 
estimate of observed lead exposure at window j 
The estimated lead effect at each following window j integrates the effects of 
exposures from both current window and past windows via secondary endogenous lead 
exposure. As illustrated in Equation 2.3, the effect of X1 on Y at j=4 (*) is mediated 
through the bone- blood exchange over next three windows ("1, "2, "3). Similarly, X2, X3 
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3. CHAPTER 3 THE POTENTIAL INFLUENCE OF VARIANTS OF THE SNCA GENE 
ON THE IMPACT OF CUMULATIVE LEAD EXPOSURE ON RISK OF 
PARKINSON’S DISEASE 
Introduction 
Parkinson’s disease (PD) is one of the most common degenerative neurological 
disorders. The incidence of PD increases with age, with annual incidence rates from 20 
out of 100,000 persons at age 60 to 120 out of 100,000 persons at age 70 1. Males 
have a higher risk of developing the disease than females 2. Around 70% of PD patients 
suffer from motor symptoms such as resting tremor, slow movement (bradykinesia) and 
postural instability. The characteristic pathological finding in PD is loss of dopaminergic 
neurons in the basal ganglia and, in particular, in the substantia nigra pars compacta 
(SNpc) region. PD has a silent onset. By the time clinical symptoms arise, neuronal 
losses have occurred in around 77% of the posterior putamen, 68% of the anterior 
putamen, and 50% of the substantia nigra (SN) 3.  The prevailing view is that the loss of 
dopaminergic (DAergic) neurons in PD is a consequence of increased oxidative stress 
level and protein aggregation4-6. Both genetic and environmental components are 
involved in the disease’s development and progression. Genome-wide association 
studies (GWAS) have provided evidence of genetic contributions to the disease 7-16. 
SNCA, UCH-L1, PRKN, LRRK2, PINK1, DJ-1, and ATP13A2 have been found to be 
significantly associated with PD 16. However, family history and twin studies suggest 




in monozygotic twins and 11% or lower in dizygotic twins- was reported in the majority 
of twin studies of PD 21, 22.  
With increasing attention to effect of the environmental exposures on health, 
studies have been conducted assessing the potential contribution to the etiology of PD 
of environmental chemical exposures. For example, 1-methyl-4-phenyl-1, 2,3,6-
organophosphates (MPTP) 23and paraquat 24, 25  exposures are well studied as inducers  
of Parkinsonism in animal models. A few studies have identified associations between 
metal exposure and PD26-29. Our group has previously found that cumulative exposure 
to lead (as reflected by measurements of bone lead levels) is associated with an 
increased odds of PD 30.  
In the current study, we continued the investigation of lead impacts on PD by 
examining lead effect in subjects with different levels of genetic susceptibilities to PD. In 
particular, we chose to study the potential modifying effect of the SNCA gene, which 
has been found to be linked to PD in many GWAS studies9, 10, 12, 14, 15.  In addition, 
evidence from animal studies showed that lead can induce SNCA gene expression and 
the formation of inclusion bodies, which is commonly found in PD brain tissue31, 32. This 
gives rise to our hypothesis that lead interacts with SNCA genetic variants to create a 
synergistic effect on PD. We examined the main effect of genetic markers of the SNCA 
gene as well as the interaction with cumulative exposure to lead as reflected by bone 






Parkinson’s patients were recruited from several clinics in Boston, 
Massachusetts area: the Boston University Medical Center (BUMC), the Brigham and 
Women’s Hospital (BWH), the Beth Israel Deaconess Medical Center (BIDMC) and 
Harvard Vanguard Medical Associates (HVMA).  The initial proposed recruitment was 
800 PD cases and controls, with cases made up of recently diagnosed PD populations 
(40% have symptomatic PD less than 5 years, 80% have symptomatic PD less than 10 
years). Controls were recruited from the same hospital sites as well as from participants 
in the Harvard Cooperative Program on Aging (HCPOA), participants in Normative 
Aging study (NAS) who were of the same age as PD cases and who have had bone 
lead measurements within 1 year of that of a PD case. The controls were intended to 
match PD cases on age, sex, race and geographic distributions.  
Subject Selections 
The majority of the participants in this study were American Caucasians (86.8%); 
63.2% of the total participants were males. A total of 330 PD cases were identified by 
two clinical neurologists and confirmed with neuroimaging diagnosis (CT or MRI scan) 
showing abnormal structure in basal ganglia or brainstem and exhibiting the following 
symptoms: resting tremor, cogwheel rigidity, bradykinesia. Medical charts was reviewed 
by a study neurologist and additional neurologist affiliated with our collaborating clinics. 
Specifically, cases were selected based on the following criteria: (1) complete history 




three symptoms: resting tremor, cogwheel rigidity, bradykinesia; (3) asymmetry; (4) 
none of the following: supranuclear gaze palsy out of proportion for PD, unexplained 
cerebellar findings, unexplained hypperreflexia, definite absence of response to 
levodopa 600mg/day, clearly nonprogressive course, findings strictly unilateral after 5 
years, MRI or CT showing infarcts in the basal ganglia or brainstem with either stepwise 
clinical progression, lower-body predominance or pyramidal signs, neuroleptic use in 
the past 6 months; (5) at least two clinical evaluations at a minimum of six months apart, 
the last one of which must be within twelve months prior to recruitment for this study, in 
which preceding criteria were met; and (6) symptoms of PD for fewer than ten years.   
A total of 354 control subjects were mainly recruited from two populations. 
Spouses and in-laws were the first consideration of controls due to the little likelihood of 
being genetically associated with cases. Subjects were free from PD or did not exhibit 
any PD like symptoms, did not have 1st or 2nd degree blood relative with confirmed or 
suspected PD case. Subjects who were younger than 50 years old and/or living more 
than a 2-hour drive from Boston were not considered. Given the lack of an adequate 
number of successfully recruited controls from the originally proposed population, 
subjects participating in the Normative Aging Study (NAS) who were free of PD were 
adopted based on matching demographic information. Of the controls, 59.6% were the 
spouses, in-laws and friends of the PD subjects, and 40.4% were selected from 
subjects participating in the long-running Normative Aging Study (NAS) and 
communities (HCPOA).  
This study was approved by Human Research Committee of Harvard School of 




Medical Center (BIDMC) and Harvard Vanguard Medical Associates (HVMA). All 
subjects in this study had been informed and consented to participate.  
Retrospective Lead Exposure  
Bone lead levels were measured non-invasively using a 109Cd K-shell X-ray 
fluorescence (K-XRF) 33, 34 instrument at the Harvard University/Channing laboratory. 
Subjects who consented to take lead measurements were asked to take two 30-minute 
in vivo bone lead measurements at clinic visit. The left tibia and patella were selected to 
represent the lead depositions in cortical and trabecular bones. The physical principle, 
technical specifications were described in Aro et al’s paper 35. As a quality control 
measure, lead exposure measurements with estimated uncertainties greater than10µg/g 
in tibia and greater than15µg/g in patella were excluded. Both tibia and patella lead level 
reflect cumulative exposure to lead. Compared to patella lead, tibia lead, which is made 
up primarily of cortical bone, exhibits a lower decay rate over time due to the limited 
bone-blood lead exchange 36. Therefore tibia lead is considered as a reliable biomarker 
for lifetime lead exposure. By contrast, the patella, which is mostly trabecular bone, has 
a proportionately larger surface area in contact with blood and the associated lead 
content decays faster than that of tibia lead. Comparing and contrasting the effect of 
these two biomarkers helps to determine the relevant exposure interval for any 
associations.    
Other Information  
A series of questionnaires were conducted during initial recruitment. The 




lifestyle, environmental and occupational exposures, food consumption frequencies and 
tobacco use. Two updated versions that have been conducted with and without 
repetition in study subjects.  
Genotyping and Quality Control  
A total of 14 candidate SNPs in the SNCA gene from 548 study subjects’ DNA 
samples were genotyped at Channing lab at the Harvard University. The markers from 
14 loci were selected based on previous literature, showing an association between 
these common markers and the risk of PD pathology 7, 11, 14, 37-47. DNA was extracted 
from whole blood using standard techniques. Genotyping was done by Sequenom 
iPLEX SNP genotyping technique.  
We defined a call rate threshold at 0.9 for each marker and 0.6 for each 
individual sample as quality filters before analysis. We compared the call rates between 
cases and controls. We defined the threshold of minor allele frequency at 5% and 
compared allele frequency and heterozygosity rate between cases and control groups. 
Departure from Hardy-Weinberg equilibrium was calculated in the pooled study 
population and in cases and controls separately. Linkage disequilibrium (LD) 
examination was defined as r2 greater than 0.8 and D’ greater than 0.9.  
Statistical Analyses 
All of the statistical procedures were performed in R version 2.15.2 48. Packages 
genetics 49 and CGEN 50  and visreg 51 were installed for genetic data processing. The 
threshold for statistical significance were determined at p <0.05. Prior to data analysis of 




variables of interests in cases and controls between included and excluded datasets, in 
order to examine the variable distribution shifts brought by data attrition from merging 
with genotype data. We performed logistic regressions to examine the main effect of 
lead in the final dataset and compared this to the effect estimates from the original 
exposure-only dataset, which included fewer NAS subjects compared to the dataset 
published30. Bone lead levels were categorized into quartiles. The OR of PD in each 
quartile was estimated using logistic regression. Comparisons were made of ORs from 
the final dataset and from the exposure dataset with those that have previously been 
published30 to examine differences in the main effects of bone lead in the final dataset.  
Univariate and Bivariate Analyses 
The distributions of tibia and patella lead levels were examined for normality and 
variance. Lead was treated as a continuous variable in the final model. After accounting 
for age, age squared, sex, race, smoking status, and educational levels, bone lead 
distributions in the HCPOA, NAS and community controls were equivalent to the bone 
lead distributions in the BUMC controls (tibia difference: 1.17µg/g, p=0.59, patella 
difference: 0.26µg/g, p=0.92). Therefore, controls from HCPOA, NAS and community 
were merged into BUMC control group. Education levels were categorized into high 
school diploma or less, some college, college graduate, graduate school and others. 
Race information was dichotomized into Caucasians and others. For the covariates with 
missing information (< 8% for any covariates in the final models), we created separate 
missing categories and included them into the final models. We assigned the median 
value to any missing data in pack-years of cigarette smoking, and created missing 




models. Genotypes were categorized into having 0, 1, 2 copies of the dominant alleles. 
We then compared genotype frequency by disease status, gender, race and recruitment 
sites; we also examined bone lead levels, age at lead measurements, age at 
appearance of first PD symptoms, and age at PD diagnosis by genotypes. 
Association Tests 
Fisher’s exact tests and Cochran-Armitage trend tests were performed among 
the 14 markers to examine their main effects. Statistical significance was considered but 
not determined using Bonferroni correction across the number of tested loci, which 
renders p value threshold at 0.05/14. Our analyses constituted two stages; before 
testing the gene-environment interaction effects, polytomous logistic regressions were 
performed to examine the degrees of independence between selected loci and bone 
lead levels (%GE). This step served as an alert for potential biases if any associations 
were found between genotype distributions and lead exposures, then unconditional 
logistic regression and empirical bayes logistic regression models 52, 53 were used to 
estimate the gene-environment interaction effects. The results from both methods are 
reported here. Due to the break of matching on the matching variables in the final 
dataset, all models included age, sex, race, recruitment sites, educational levels and 
cigarette smoking pack-years as covariates.  
Results 
All 14 SNCA markers reached a call rate above 0.9. Eleven individuals were 
filtered out due to call rates less than 0.6. The overall call rate for all individuals was 




minor allele frequencies (MAF) of the selected markers were all above 5%. Allele 
frequency and heterozygosity were not significantly different between cases and 
controls. Departure of Hardy-Weinberg disequilibrium was identified in six markers at 
p<0.05 (Figure S 3.1). Figure 3.1 shows the chromosome physical distance of 14 SNCA 
markers. Six marker pairs were detected in high LD (r2>0.8, D’>0.95) (Figure S 3.2). A 
total of 537 subjects were maintained in the genotype dataset. After combining with the 
lead exposure dataset, 535 subjects with complete information were included in the final 
dataset. Prior to the main analysis, the sensitivity analysis showed that the main effect 
estimates of lead on risk of PD from the final dataset were not meaningfully different 
from the lead effect estimates from the published dataset30(Table S 3.1).  
Table 3.1 lists the distributions of each variable in the final models for the pooled, 
final, and excluded datasets and by disease status. In general, the controls who entered 
into the final dataset were younger, lighter smokers, compared to cases. In the final 
dataset, the average age at bone lead measurement was 66.6 years in cases 
(SD=9.34) and 69.13 years in controls (SD=9.72), and the mean age of subjects at time 
of PD diagnosis was 60 years (range 28.5-83.91, SD=10.99). After adjusting for age, 
age squared, educational levels, years of smoking, sex and race, the bone lead level in 
a White female aged 50 years with a college degree was 3.85 µg/mg in tibia and 2.46 
µg/mg in patella in the final dataset, whereas in the excluded subjects an equivalent 
subject’s tibia level was 4.46 µg/mg in tibia and 3.61 µg/mg in patella. 
Allele frequencies in the final dataset are shown in Table 3.2. No significant 
differences in allele frequencies were found between case and control groups (Table 




difference was observed in allele frequency between genders (data not shown). The 
allele frequency in the majority of the markers was significantly different between whites 
and nonwhites (data not shown) at p<0.05. Allele frequencies of all makers were 
comparable to the reference population (HapMap CEU). The genotype frequencies for 
all 14 loci among cases and controls are given in Table 3.3. Markers rs10005233, 
rs2301134, rs2301135, rs356186, and rs356188 had different genotype distributions 
between cases and controls at p<0.05. Tibia and patella lead levels did not differ by 
genotypes for any of the 14 markers at p<0.05. The onset of PD was not associated 
with any genotype groups of all makers at p<0.05.  
The initial association tests showed statistical significance at p<0.05 at loci 
rs356188, rs356186, rs10005233, rs2301135, and rs2301134, on Fisher’s exact tests 
and at loci rs356188, rs356186, rs2301135, rs2301134 and rs2736994 on Cochran-
Armitage trend tests (Figure S 3.3, Figure S 3.4). However, after Bonferroni correction, 
only marker rs2301135 reached statistical significance. The gene-environment 
independence assumption tests in control subjects showed that, in general, the 
association between bone lead levels and genotype frequency is weak (%GE range: -
0.054, 0.066,Table S 3.2). However, several markers reached statistical significance at 
p<0.05, indicating significant gene-environment dependence. After Bonferroni 
corrections for 14 loci (p= 0.0036), none of the models reached statistical significance. 
Since under the gene-environment dependence condition, case-only estimates of 
interaction term are subject to bias; furthermore, empirical bayes method weighs 
between the effect estimates using case-only method and the effect estimates using 




Therefore, we decided to report effect estimates based on the unconditional logistic 
regression method. Interaction term effect estimates were plotted in Figure S 3.5, Figure 
S 3.6 for comparison purposes.   
After adjusting for age, educational level, race, gender, and pack-years of 
cigarettes smoking in the gene-environmental final models, we found no significant 
associations between bone lead levels and PD status in any models. The effect of bone 
lead with one standard deviation increase is listed in Table S 3.4. We found strong and 
significant main effects of markers at loci rs11931074, rs356186, rs1812923, 
rs10005233 rs2301135 rs2301134 and rs2736994 on PD (Table 3.4, 3.5). The ORs 
comparing homozygote of minor alleles are 0.494 (95%CI: 0.20,1.20) for heterozygote, 
0.31 (95%CI: 0.12, 0.75) for homozygotes at rs1812923; 1.56 (95%CI: 0.77, 3.14) for 
heterozygotes and 4.29 (95%CI: 1.77, 10.39) for homozygotes at rs10005233; 2.07 
(95%CI: 1.03, 4.15) for heterozygotes, 5.74 (95%CI: 2.26, 14.57) for homozygotes at 
rs2301135; and 0.38 (95%CI: 0.16, 0.89) for heterozygotes, 0.21 (95%CI: 0.08, 0.53) 
for homozygotes at rs2301134 in the tibia bone lead models. Similar results were found 
in patella bone lead models. Since rs10005233, rs2301135 and rs2301134 were in high 
mutual LD, we chose to report rs2301135 in this analysis, based on p values of main 
effect of the markers from both tibia and patella logistic regression models. The 
markers’ main effects remained significant after the post-hoc adjustment. 
Additionally, we found that the gene-environment interaction effects were 
significant at loci rs1812923, rs2301135 in tibia lead models at p<0.05, and marginal 
significance (p<0.1) at loci rs1193107, rs356221 and rs2736994. After Bonferroni 




statistical significance. The results for the main effects of each genotype and the 
interactions between genetic variant and bone lead levels shown in Table 3.4 and 3.5. 
Figure 3.2 depicts dose-response relationships between bone lead and probability of 
being a PD case by genotype in markers rs1812923, rs2301135, and rs2736994. As 
shown in the plots for the genotype at locus rs1812923, subjects with homozygous A 
allele (G0) showed the highest odds of having PD compared to heterozygous subjects 
(G1) and homozygous subjects carrying the C allele (G2). However, the dose-response 
relationship showed that the probability of having PD in G0 subjects was not affected by 
an increased level of bone lead, whereas in the G1and G2 groups, an elevated bone 
lead level is associated with an increasing probability of being a PD case. In the tibia 
model, the interaction term OR for G1 was 1.09 (95%CI: 1.00, 1.18, p= 0.04) and OR for 
G2 was 1.08 (95%CI: 0.99, 1.18, p= 0.06). As for the locus rs2301135, the main effect 
of the C allele homozygote (G0) showed a protective effect compared with 
heterozygotes (G1) and G allele homozygotes (G2). In the G0 group, an increase in 
bone lead was associated with a greater probability of being a PD case; whereas in the 
G1 group the same direction of association was observed with lesser magnitude (OR= 
1.03, 95%CI: 0.96,1.09, p= 0.41). In the G2 group, increased lead was associated with 
decreased probability of being a PD case with an OR of 0.91 (95%CI: 0.84,0.99, p= 
0.03). Similar patterns was observed at locus rs2736994, with marginal significance (p= 
0.08 for the interaction term in G1 (CT) and a p value of 0.47 for the interaction term in 
G2 (TT). In group G0 (CC), being a PD case was not associated with lead levels, 
whereas in the G1, G2 groups, increased bone lead levels were positively associated 




an increase in education level (result not shown). However, these test results did not 
reach statistical significance in most models.  
Discussion  
This study is the first to report an analysis of the potential interactions between 
markers in the SNCA gene and cumulative environmental lead exposure risk on 
Parkinson’s disease. In these analyses of a subset of subjects from the parent study, 
we found that none of the main effect estimates of bone lead was significantly related to 
the odds of being a PD case, which is somewhat different than what we found in the 
parent study. However, we found significant main effects of markers on PD at loci 
rs2736994, rs1812923, rs10005233, rs2301135, and rs2301134. These results indicate 
C allele at rs2736994, the G allele at rs2301135 and the A allele at rs1812923 
detrimental effects on PD. We also found significant gene-environment interactions with 
respect to PD at loci rs1812923 and rs2301135.  The results showed that bone lead 
levels were positively associated with PD in subjects who had less genetic risk of PD; 
whereas bone lead levels were negatively associated with PD in subjects with higher 
genetic risk of PD. Most of the genetic markers locate in the introns of SNCA gene. 
rs11931074 and rs2736994 located at the upstream and downstream of SNCA gene. 
The functions of these noncoding SNPs are largely unknown.  
Our results are comparable to previously reported main effects of lead from our 
group in that lead exposure tended to increase the odds of PD, even though the effect 
we saw was not statistically significant. It also provides evidence of the dynamics of 




to our understanding of the role of lead exposure in PD development and sheds light on 
population dynamics of susceptibility to PD.  
Our results showed that tibia lead appeared to have stronger associations with 
PD in the interaction terms than patella lead. This distinction can be explained by the 
different decay rates of cortical and trabecular bone lead and may simply reflect the 
different value of these bone measurements in representing retrospective exposures 36. 
The implication from this difference is that effect of lead on PD is more likely due to 
cumulative exposures rather than secondary endogenous exposure. This contention 
has been well discussed in our previous work30.  
The SNCA gene encodes !-synuclein, a brain-enriched neuron specific protein 
that binds phospholipid membranes at synaptic vesicles. It localizes at the pre-synaptic 
terminals in the mature neurons and can be found in both axons and dendrites in 
immature neurons 54.The expression of SNCA is involved in synaptic plasticity and 
synapse maturation 54. In SNCA knockout mice reductions in striatal dopamine levels 
and in the corresponding dopamine dependent locomotory activities were observed 55. 
"-synuclein can bind to tyronsine hydroxylase and inhibits dopamine synthesis 56. It also 
increases the dopamine transporter (DAT) localization at cell surface by binding to DAT. 
This leads to an increase of dopamine reuptake, thus elevating intracellular dopamine 
level and creating oxidative stress 57.  
!-synuclein and PD 
At physiological pH !-synuclein, especially in mutated form, has the propensity to 




major component of the Lewy body 59, the pathological finding commonly seen in PD 
brains 60. The oligomeric form of "-synuclein has a detergent-like property and forms 
pores in lipid membrane. This results in the increased permeability of cell membranes 
61, 62, which can lead to cell death at severe extent. Aggregated "-synuclein can activate 
microglia and induces subsequent chronic inflammation in central nervous system, 
which is a well-recognized pathogenesis process of PD 63, 64. It is also observed that 
aggregated "-synuclein directly induces apoptosis of dopamine neurons 65.  
Previous genome-wide association studies 16 7, 9, 37, 38, 40, 41, 43, 66-70 have 
confirmed the role of "-synuclein in PD development. Our results are in agreement with 
previous knowledge. Specifically, we observed the deleterious effects at loci rs2736994, 
rs1812923, rs10005233, rs2301135, and rs2301134. Due to the fact that rs10005233, 
rs2301135, and rs2301134 were in pair wise LD, we chose to report rs2301135 to 
represent the genetic effects in this region. SNPs rs1812923, rs2301135 and rs2736994 
exhibit additive effects, with an increase in the number of detrimental alleles (the minor 
allele A in rs1812923; the major allele G in rs2301135 and the minor allele C in 
rs2736994) associated with increasing likelihood of being a PD case in tibia lead 
models.  
Lead Effect on PD by SNCA Variants 
In addition to the findings on the main effect of the SNPs, we also observed 
significant interaction effects at loci rs1812923 and rs2301135. It is noteworthy that 
among all these loci, the increased odds of being a PD case from higher lead exposure 




homozygous deleterious alleles, elevation of bone lead level did not increase the odds 
of being a PD case. In some cases, increase in bone lead levels was negatively 
associated with odds of being a PD case. This result suggests that lead’s impact on PD 
depends on genetic predispositions. It also suggests that lead exposure and genetic 
predisposition in SNCA gene does not have a synergistic effect on PD development. In 
addition, we did not observe that genotypes of SNCA were strongly associated with 
bone lead levels. This indicates that SNCA gene does not modify the toxicodynamics of 
lead.  
The mechanism of lead exposure contributing to the risk of PD is not clearly 
understood. However, evidence suggests that lead could impact on the pathogenesis of 
PD via the oxidative stress mechanism, since lead is a known prooxidant. Lead induces 
oxidative stress by binding with &-Aminolevulinic acid dehydratase (&-ALAD) in 
erythrocytes 71, 72, inhibiting the reductase activities73, 74, interfering with intracellular 
Ca2+ activities 75, 76 and inhibiting mitochondria functions 77, 78. Dopamine neurons are 
particularly susceptible to oxidative stress in the physiological environment 79. 
Dopamine and its metabolites generate highly reactive dopamine and DOPA quinones. 
DOPA quinnone is highly linked to current known pathogenesis of PD such as 
mitochondrial dysfunction, inflammation, oxidative stress4, and dysfunction of the 
ubiquitin-proteasome system5.  On the other hand, oxidative stress and dopamine itself 
has been shown to induce the "-synuclein aggresome, which, in turn, creates an 
unfavorable environment for the survival of dopaminergic neurons 56, 58, 80, 81. 
On the other hand, Waalkes’s et al has pointed out that the inclusion body that is 




preventing further cellular disruptions from lead by sequestering lead in the 
metallothionein (MT)- lead- "-synuclein inclusion body31, 32. In their in vitro study32, the 
researchers observed that in wild type MT mice cells, lead increased SNCA expression 
in a timely manner, which peaked at 24 hours, then subsided at 48 hours when lead-
induced inclusion body is formed. They also observed that MT knock-out mice did not 
form lead inclusion bodies and accumulated less lead in kidney after lead exposures31. 
These mice exhibited dose-related nephromegaly, and their renal functions were 
significantly diminished after lead exposures31.  
Weighing the dual roles that "-synuclein plays in the context of lead- related PD, 
our results, to some extent, supported biological findings from animal studies. Our 
results showed an interactions between lead and SNCA genetic variants in such a 
pattern that increased lead was not associated with an increased odds of PD in subjects 
who were genetically susceptible to PD.  We can postulate that in these subjects, "-
synuclein, per se, may have a tendency to form aggresomes, thus creating unfriendly 
environments for dopaminergic neurons; while on the other hand, due to the inclusion 
body formation, it prevents lead interfering with cellular machineries and buffers lead’s 
impact on neurons. Therefore, we observed that lead increased the odds of PD in 
subjects with less genetic susceptibility, possibly due to a decrease in inclusion body 
formation. 
However, the interpretation of our results needs to be made with caution. Our 
results may not be put into direct comparisons with those from Waalkes et al’s work in 
several respects. In the in vitro study, the cells were cultured with an exceedingly high 




achieved at physiological level in human beings. Not only is it impossible for a subject to 
be exposed at this high level environmentally, but it also has to be taken into 
consideration that due to the blood brain barrier protection, the biological dose of lead 
entered into neurons is substantially lower. Secondly, all observations from Waalkes et 
al’s work were made in renal cells. Compared to neurons, inclusion bodies are more 
commonly observed in kidney cells. Thirdly, the researchers pointed out the crucial role 
of MT in the inclusion body formation process. Our study did not examine the effects of 
genetic variants in MT gene interacting with SNCA gene and lead exposure. It would 
provide great insights on disease mechanism if we could consider the potential 
modifying effect of MT gene into our study. Finally, the functions of these SNPs are 
unclear; we only postulated that the detrimental effect from these loci may be related to 
"-synuclein aggresome formation. Biological studies are needed to further confirm this 
contention.  
In addition, our results should be placed in limited context. Over one third of the 
control subjects failed to enter into the genotype data. The sample size in the final 
dataset was substantially reduced in comparison to the parent study. Our sensitivity 
analysis showed lead effects contrasted by quartiles were underestimated compared to 
our previous report. In addition, the statistical power was substantially compromised due 
to the reduced sample size. Many of our results were significant only at the p<0.05 
levels. Our results are preliminary and would need replication in other study settings.  
In summary, this study considered the roles of markers from SNCA gene in 
dopaminergic system for Parkinson’s disease. We examined the main influence of 




rs2736994, rs1812923, and rs2301135 significantly predicted PD status. Lead 
increased the odds of PD only among subjects who were less genetically susceptible. 
Subjects with higher genetic susceptibility were less affected by lead exposure.  Our 
findings were consistent with current knowledge on genetic etiology of PD and our 
previous findings on main effect of environmental lead exposure. These results are 
clearly preliminary and are in need of replication. Future work is needed to better 















                                            
11 The pooled dataset contained fewer Normative Aging Study subjects compared to published data. 
   Total Pool of Subjects11  Included in Gene-Environment Study 
  
Excluded from Gene-Envrionment Study 
  Non-PD PD Non-PD PD Non-PD PD 
 N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 
Sex  [N (%)] 297 0.56 - 375 0.37 - 207 0.66 - 328 0.37 - 90 0.32 - 47 0.38 - 
Whites [N (%)] 281 0.84 - 354 0.96 - 192 0.85 - 307 0.96 - 89 0.83 - 47 0.96 - 
Age at Pb measures 274 69.99 9.82 340 66.46 9.39 204 69.13 9.72 327 66.60 9.34 70 72.48 9.78 13 62.91 10.33 
Birth Year 274 1936.90 9.77 340 1939.20 9.45 204 1937.63 9.63 327 1939.07 9.40 70 1934.77 9.94 13 1942.51 10.42 
Education level 279 3.63 1.11 353 3.94 1.11 190 3.76 1.08 306 3.98 1.08 89 3.37 1.13 47 3.68 1.27 
Years of Smoking 273 13.01 15.51 278 8.00 12.12 202 12.25 14.83 265 8.00 12.08 71 15.15 17.23 13 8.00 13.52 
Pack -years  273 10.91 17.65 301 7.07 13.65 202 9.15 15.87 288 7.28 13.88 71 15.95 21.26 13 2.48 4.92 
Age of PD Onset 0 - - 209 57.67 12.06 0 - - 203 57.65 12.09 0 - - 6 58.52 12.21 






Table 3.2 Allele Frequency in Case and Control Groups 
   Pooled  PD  Non-PD  
Reference 
Population12 
Markers  A1 A2 A1 A2 A1 A2 A1 A2 A1 A2 
rs356219 A G 0.56 0.44 0.55 0.45 0.58 0.42 0.58 0.43 
rs11931074 G T 0.88 0.12 0.88 0.12 0.89 0.11 0.92 0.08 
rs356221 A T 0.54 0.46 0.55 0.45 0.53 0.47 0.47 0.53 
rs356168 G A 0.54 0.46 0.55 0.45 0.53 0.47 0.47 0.53 
rs356188 A G 0.79 0.21 0.81 0.19 0.76 0.24 0.84 0.17 
rs356186 G A 0.80 0.20 0.82 0.18 0.77 0.23 0.86 0.14 
rs2737029 A G 0.55 0.45 0.54 0.46 0.56 0.44 0.55 0.45 
rs1812923 C A 0.59 0.41 0.56 0.44 0.62 0.38 0.50 0.50 
rs10005233 C T 0.51 0.49 0.52 0.48 0.56 0.44 0.47 0.54 
rs2301135 C G 0.52 0.48 0.51 0.49 0.57 0.43 0.50 0.50 
rs2301134 T C 0.52 0.48 0.51 0.49 0.57 0.43 0.48 0.52 
rs2619364 A G 0.71 0.29 0.71 0.29 0.70 0.30 0.68 0.32 
rs2583988 C T 0.71 0.29 0.72 0.28 0.70 0.30 0.74 0.26 





                                            






Table 3.3 Genotype Frequency between Cases and Controls 
 Non-PD PD  Pooled    
Markers  G0 G1 G2 G0 G1 G2 G0 G1 G2 p value 13 
rs10005233 0.34 0.43 0.23 0.24 0.49 0.27 0.28 0.47 0.26 0.04 * 
rs11931074 0.83 0.13 0.05 0.79 0.18 0.03 0.80 0.16 0.04 0.18  
rs1812923 0.17 0.41 0.41 0.20 0.48 0.33 0.19 0.45 0.36 0.12  
rs2301134 0.21 0.43 0.36 0.25 0.52 0.23 0.23 0.48 0.28 0.01 ** 
rs2301135 0.37 0.41 0.22 0.23 0.52 0.25 0.28 0.48 0.24 0.00 ** 
rs2583988 0.53 0.33 0.14 0.52 0.39 0.09 0.52 0.37 0.11 0.16  
rs2619364 0.52 0.34 0.14 0.51 0.40 0.09 0.52 0.37 0.11 0.16  
rs2736994 0.58 0.34 0.08 0.64 0.33 0.03 0.61 0.33 0.05 0.06  
rs2737029 0.32 0.47 0.21 0.29 0.50 0.21 0.30 0.49 0.21 0.68  
rs356168 0.24 0.46 0.30 0.23 0.43 0.34 0.23 0.44 0.32 0.76  
rs356186 0.07 0.31 0.62 0.03 0.30 0.67 0.05 0.31 0.65 0.05 * 
rs356188 0.60 0.33 0.08 0.66 0.31 0.03 0.63 0.32 0.05 0.04 * 
rs356219 0.37 0.41 0.22 0.33 0.43 0.24 0.34 0.43 0.23 0.60  
rs356221 0.30 0.46 0.24 0.34 0.43 0.23 0.32 0.44 0.23 0.70  
 
 
                                            




Table 3.4 Markers’ Main Effects and Interaction Effects from Tibia Lead Models14  
 Main Effects of Markers Lead x Markers Interaction Effects No. of Observations in Each Group 
Markers OR LCI UCL OR LCI UCI G0 G1 G2 PD Non-PD 
rs356219 0.86 0.43 1.75 1.04 0.98 1.11 162 205 115 298 184 
  1.16 0.50 2.72 1.01 0.93 1.09 162 205 115 298 184 
rs11931074 0.93 0.37 2.37 1.07 0.98 1.17 393 78 18 302 187 
  6.76 0.77 59.48 0.86 0.73 1.02 393 78 18 302 187 
rs356221 0.53 0.26 1.09 1.06 0.99 1.13 161 215 109 300 185 
  0.68 0.28 1.66 1.04 0.96 1.12 161 215 109 300 185 
rs356168 0.86 0.39 1.89 1.02 0.95 1.09 110 216 161 302 185 
  1.57 0.65 3.79 0.96 0.89 1.04 110 216 161 302 185 
rs356188 0.56 0.28 1.12 1.03 0.97 1.10 307 156 24 301 186 
  0.35 0.09 1.41 1.01 0.88 1.16 307 156 24 301 186 
rs356186 2.26 0.41 12.37 0.99 0.84 1.16 22 150 312 300 184 
  4.85 0.94 25.10 0.94 0.80 1.10 22 150 312 300 184 
rs2737029 1.09 0.53 2.24 1.01 0.95 1.08 144 240 104 302 186 
  0.99 0.41 2.36 1.01 0.93 1.09 144 240 104 302 186 
rs1812923 0.49 0.20 1.20 1.09 1.00 1.18 87 220 177 300 184 
  0.31 0.12 0.75 1.08 1.00 1.18 87 220 177 300 184 
rs10005233 1.56 0.77 3.14 1.03 0.97 1.10 137 228 123 302 186 
  4.29 1.77 10.39 0.93 0.86 1.01 137 228 123 302 186 
rs2301135 2.07 1.03 4.15 1.03 0.96 1.10 140 230 115 300 185 
  5.74 2.26 14.57 0.91 0.84 0.99 140 230 115 300 185 
rs2301134 0.38 0.16 0.89 1.11 1.02 1.20 113 234 140 301 186 
  0.21 0.08 0.53 1.07 0.99 1.17 113 234 140 301 186 
rs2619364 0.83 0.43 1.62 1.05 0.98 1.11 249 180 53 298 184 
  0.55 0.22 1.38 1.00 0.91 1.09 249 180 53 298 184 
rs2583988 0.85 0.44 1.64 1.04 0.98 1.10 254 179 53 301 185 
  0.57 0.23 1.42 1.00 0.92 1.09 254 179 53 301 185 
rs2736994 0.45 0.23 0.90 1.06 0.99 1.12 296 164 25 301 184 
  0.31 0.08 1.17 1.05 0.92 1.19 296 164 25 301 184 
 
                                            
14 All markers were treated as categorical variables, no inherit mode was assumed, G0 as reference group. The tibia lead levels were treated as 




Table 3.5 Markers’ Main Effects and Interaction Effects from Patella Lead Models15  
 Main Effect of Markers Lead x Markers Interaction Effect No. of Observations in Each Group 
Markers  OR LCI UCI OR LCI UCI G0 G1 G2 PD  Non-PD 
rs356219 1.08 0.54 2.17 1.01 0.96 1.06 160 200 113 293 180 
  0.86 0.37 1.99 1.03 0.97 1.09 160 200 113 293 180 
rs11931074 0.87 0.36 2.10 1.07 1.00 1.14 385 78 17 297 183 
  9.33 0.90 97.17 0.88 0.76 1.02 385 78 17 297 183 
rs356221 0.68 0.33 1.40 1.02 0.97 1.07 158 211 107 295 181 
  1.00 0.43 2.33 0.99 0.94 1.05 158 211 107 295 181 
rs356168 0.80 0.37 1.71 1.02 0.96 1.07 108 212 158 297 181 
  1.06 0.46 2.46 1.00 0.95 1.06 108 212 158 297 181 
rs356188 0.93 0.48 1.81 0.98 0.93 1.02 301 153 24 296 182 
  0.45 0.09 2.26 0.98 0.88 1.09 301 153 24 296 182 
rs356186 2.79 0.46 16.77 0.98 0.87 1.10 22 147 306 295 180 
  3.03 0.53 17.31 1.00 0.90 1.12 22 147 306 295 180 
rs2737029 1.02 0.50 2.07 1.01 0.97 1.07 142 235 102 297 182 
  0.65 0.27 1.56 1.05 0.98 1.11 142 235 102 297 182 
rs1812923 0.70 0.30 1.67 1.03 0.97 1.10 87 213 175 295 180 
  0.42 0.17 1.04 1.03 0.97 1.10 87 213 175 295 180 
rs10005233 2.02 0.98 4.16 1.00 0.95 1.05 135 222 122 297 182 
  2.80 1.17 6.70 0.99 0.93 1.05 135 222 122 297 182 
rs2301135 2.96 1.43 6.10 0.99 0.94 1.04 138 224 114 295 181 
  3.97 1.61 9.79 0.96 0.91 1.02 138 224 114 295 181 
rs2301134 0.71 0.31 1.63 1.02 0.96 1.08 112 228 138 296 182 
  0.29 0.12 0.70 1.03 0.96 1.09 112 228 138 296 182 
rs2619364 0.85 0.43 1.66 1.03 0.99 1.08 246 176 52 294 180 
  0.39 0.14 1.03 1.03 0.96 1.11 246 176 52 294 180 
rs2583988 0.84 0.43 1.63 1.03 0.98 1.08 250 175 52 296 181 
  0.39 0.15 1.03 1.04 0.96 1.11 250 175 52 296 181 
rs2736994 0.81 0.41 1.57 0.99 0.95 1.04 291 160 25 296 180 
  0.41 0.11 1.63 1.00 0.91 1.11 291 160 25 296 180 
 
                                            
15 All markers treated as categorical variables; no inherit mode was assumed; G0 as reference group. The patella lead levels were treated as 






Table S 3.1 Tibia Lead Main Effects in the Final Dataset 
 All sites (n=531)16  All hospital sites (exclude HCPOA) (n=400)17 
Tibia Lead (µg/g) Non-PD PD OR LCI UCI Tibia Lead (µg/g) Non-PD PD OR LCI UCI 
!1.74 53 84 - - - !1.74 26 84 - - - 
1.74-7.83 54 83 1.32 0.73 2.40 1.74-7.83 18 83 1.32 0.62 2.81 
7.83-13.92 48 89 1.51 0.83 2.77 7.83-13.05 15 77 1.50 0.69 3.28 
>13.92 49 71 1.66 0.88 3.15 >13.05 14 83 1.73 0.77 3.87 











                                            
16 The final dataset for gene-environment interaction models 





Table S 3.2 Gene-Environment Independence Test Results 
 Tibia Lead Models  Patella Lead Models  
 G1   G2   G1   G2   
Markers "GE p value 18 "GE p value  "GE p value  "GE p value  
rs10005233 0.002 0.90  0.035 0.06 . 0.012 0.37  0.009 0.59  
rs11931074 -0.016 0.43  0.062 0.04 * -0.004 0.82  0.032 0.20  
rs1812923 -0.019 0.34  -0.026 0.20  -0.006 0.71  -0.009 0.60  
rs2301134 -0.034 0.07 . -0.037 0.05 . 0.004 0.78  -0.014 0.40  
rs2301135 0.002 0.91  0.051 0.01 * 0.018 0.21  0.029 0.07 . 
rs2583988 -0.029 0.06 . -0.016 0.45  -0.008 0.53  -0.048 0.02 * 
rs2619364 -0.031 0.04 * -0.020 0.33  -0.011 0.43  -0.044 0.03 * 
rs2736994 -0.015 0.30  -0.021 0.41  0.015 0.25  -0.007 0.77  
rs2737029 -0.009 0.58  -0.003 0.89  -0.001 0.92  -0.014 0.42  
rs356168 -0.007 0.70  0.023 0.22  -0.002 0.89  0.016 0.33  
rs356186 0.002 0.95  0.016 0.55  -0.007 0.75  -0.021 0.34  
rs356188 -0.005 0.73  -0.001 0.98  0.013 0.32  0.028 0.17  
rs356219 -0.024 0.13  0.005 0.79  0.006 0.64  -0.009 0.59  







                                            





Table S 3.3 Standardized Coefficients of Main Effects of Bone Lead from Gene-Environment Interaction Models  
 Tibia Lead Models Patella Lead Models 
Markers Std. OR Std. SE p value  Std. OR Std. SE p value  
rs356219 0.01 0.20 0.94  -0.02 0.20 0.91  
rs11931074 0.17 0.12 0.17  0.04 0.13 0.77  
rs356221 -0.03 0.19 0.86  0.00 0.17 0.98  
rs356168 0.15 0.22 0.52  -0.07 0.23 0.78  
rs356188 0.13 0.14 0.37  0.21 0.15 0.15  
rs356186 0.13 0.55 0.81  0.00 0.51 1.00  
rs2737029 0.09 0.20 0.64  -0.16 0.21 0.43  
rs1812923 -0.43 0.30 0.16  -0.19 0.26 0.47  
rs10005233 0.14 0.20 0.48  0.17 0.22 0.43  
rs2301135 0.18 0.20 0.37  0.29 0.22 0.19  
rs2301134 -0.58 0.31 0.06  -0.16 0.27 0.56  
rs2619364 0.03 0.16 0.85  -0.15 0.16 0.33  
rs2583988 0.07 0.15 0.63  -0.15 0.16 0.35  




























Figure 3.2 Bone Lead Levels and Probability of PD by SNCA Genotypes  







Figure S 3.1 –Log10 (p value) from Hardy-Weinberg Tests  





Figure S 3.2 High Linkage Disequilibrium Pairs 




















Figure S 3.5 Interaction Effect Estimates in Tibia Lead Models (Unconditional Maximum Likelihood vs. Empirical 
Bayes Likelihood Estimates) 
Caption: Solid line - G1 group; dotted line - G2 group. Red - unconditional maximum likelihood (UML) estimates; blue - 
empirical bayes (EB) maximum likelihood estimates. The coefficients lack of 95%CI due to that the standard errors were 





Figure S 3.6 Interaction Effect Estimates in Patella Models (Unconditional Maximum Likelihood vs. Empirical 
Bayes Likelihood Estimates) 
Caption: Solid line - G1 group; dotted line - G2 group. Red - unconditional maximum likelihood (UML) estimates; blue - 
empirical bayes (EB) maximum likelihood estimates. The coefficients lack of 95%CI due to that the standard errors were 
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4. CHAPTER 4 CUMULATIVE EXPOSURE TO LEAD AND INCIDENCE OF TYPE-2 
DIABETES: THE VA NORMATIVE AGING STUDY 
Introduction 
Diabetes mellitus (DM) is a metabolic disorder characterized by insulin deficiency 
from loss of pancreatic beta cell or insulin resistance in peripheral tissues. Type 2 
diabetes mellitus (T2DM) is a dominant subtype of DM. Oxidative stress induced 
endoplasmic reticulum (ER) distress and systemic inflammation are the major 
pathogenic processes involved in the development of T2DM 1 2 3 4. Insulin deficiency or 
resistance can cause hyperglycemia. If untreated, hyperglycemia can lead to 
ketoacidosis or endothelial infraction, which can cause cardiac and renal function 
impairments5, 6. The incipient stage of T2DM is characterized by hyperglycemia, 
polyuria, polydipsia, polyphagia and weight loss. Early stage T2DM patients typically are 
overweight, with BMI greater than 25, or have excessive body fat around abdominal 
region7, 8. 
According to the Centers for Disease Control and Prevention, there were 1.9 
million incident cases of T2DM in people aged 20 or older in 20108. 18.8 million 
prevalent T2DM cases were recorded, which approximately 8.3% of the US population 
in year 2010. Furthermore, 7 million additional people were suspected to be 
undiagnosed and an estimated 79 million were pre-diabetic. Specifically 11.3% of 
population in age 20 and older and 26.9% of population in age 65 and older were 




million in 20109. Even with increasing attention and interventions directed towards 
diabetes prevention, the incidence rate is still increasing. In 2001, CDC predicted that 
by the year 2050 the national DM prevalence would be 7.9% of the population, an 
estimated 29 million DM cases10. However the growth of DM in recent years has 
exceeded the predictions. Along with this rapid increase in incidence, the financial 
burden associated with diabetes healthcare and treatment for related complications also 
increased concurrently11.Therefore, in order to understand and control the epidemic of 
T2DM, more knowledge on the etiology of T2DM are needed.  
Genetic inheritance plays a role in the development of T2DM12. However, 
genetics alone cannot fully explain the emerging epidemic of T2DM observed in the 
recent decades, as genetic drift would need a long period to manifest phenotypes at the 
population level. Unhealthy diet, physical inactivity, obesity, aging, race, cigarette 
smoking and poor nutrition during pregnancy are well-known non-genetic risk factors for 
T2DM 13, 14. Growing evidence has shown that environmental chemical exposure is 
another non-negligible aspect in the etiology of T2DM. Heavy metals, such as arsenic 
and cadmium, can exacerbate oxidative stress and trigger inflammation processes 
creating an environment poorly suited for the survival of pancreas cells (examples: 
Arsenic 15-17, cadmium 18, 19 nickel and mercury20).  
Despite the established link between exposure to heavy metals and T2DM, few 
studies have been conducted to explore the role of environmental lead exposure in the 
etiology of T2DM. Lead is a pro-oxidant divalent metal21-24 that can induce oxidative 
stress through direct impact on cell membranes23, interactions with !-aminolevulinic 




is known to disrupt endocrine functions, especially estrogen metabolism28 . Therefore, it 
is biologically plausible to hypothesize that lead exposure may contribute to the T2DM 
risk. We examined the association between cumulative exposure to lead, as measured 
in bones, and incident T2DM in a community-based cohort of men.  
Methods 
Study Design  
This analysis is nested in the Normative Aging Study (NAS), which was initiated 
by a multidisciplinary investigation team in early 1960’s. The study was established in 
order to study the process of healthy aging. Each individual in the study undergoes a 
series of physical examinations in the following domains: biochemistry, clinical 
medicine, oral medicine, neurology, anthropometry, psychology and sociology. Clinical 
examinations were performed every five years in subjects younger than 50 and every 
three years in subjects 50 and older. Bone lead measurements were conducted from 
1991 to 2002, with up to four consecutive measurements at tibia and patella bone sites. 
A graphical representation of exposure assessment and health outcome measurements 
is presented in Figure 4.1.  
Study Population  
The study was initially constituted of veterans from the Spanish-American war 
and later shifted to veterans who served in World War II. Subjects were enrolled through 
Veteran Administration outpatient clinics in Boston, Massachusetts. In 1972, an active 
cohort of 2032 subjects was retained in the study. Subjects were followed from 




percent a year in the early study stage. Subjects in the study were selected to represent 
a wide range of socioeconomic classes and were ensured to be geographically stable. 
In the early stage of the study, the participants were mainly middle aged, with 35 
percent of subjects aged less than 40, and 60 percent aged between 40 and 59. 
Additionally, this study excluded participants with pre-existing health conditions with 
stringent criteria. For example, subjects with blood pressure higher than 140/90 mmHg 
were excluded from the study, which led to 50% of initial elderly subject exclusions. As 
a consequence, the remainder in the study are relatively healthier compared to the 
group being filtered out 29. This selection approach can lead to a ’healthy subject’ bias, 
which was foreseen by the researchers30. The initial recruitment included a wide range 
of social economic classes. Among the recruited participants, 14 percent had less than 
high school education, 25 percent were high school graduates, 35 percent were 
educated beyond high school and 26 percent were college graduates. This population 
structure shifted upwards with additional recruitment along with the upgrading of the 
educational system in recent decades. Occupations in the original study were evenly 
spread among managers, professionals, clerks, craftsmen, as well as service workers 
and with minor representation of operatives and laborers. However, at the initial stage, 
only 2% of the study participants were African-Americans.  
The current analyses were based on this existing cohort, targeting the 
subpopulation with bone lead measurement available. A total of 878 subjects with valid 
bone lead measurements were included in the current data set. The majority of the 




Bone Lead Assessment  
Bone lead levels were measured using K shell X-ray fluorescence (K-XRF) 
approach at the Harvard University/Channing lab. Subjects who consented to lead 
measurements were asked to undergo a series of bone lead measurements at each 
clinic visit. The two bone sites were selected to represent the cortical and trabecular 
bone types. The tibia midpoint was selected to reflect lead burden in cortical bones; 
whereas patella was selected to reflect lead burden in trabecular bones. Due to low 
blood exchange rate, cortical bones have lower lead decay rate compared to trabecular 
bones therefore lead measured from cortical bones more accurately reflect the past 
history of lead exposures. Tibia lead reflects the retrospective lead exposures of the 
previous 14 to 16 years 31. Trabecular bones have higher exchange rate with blood 
compared to cortical bones and are the main contributors to endogenous lead 
exposure. In our analysis, some T2DM incidental cases occurred before the lead 
measurement. However as these two bone sites have good retention of lead and can 
refer to the exposure at retrospective time points, we decided to use the first bone lead 
measurement as a proxy of past lead exposure. To further clarify the temporality of lead 
effects with the information from two bone types, we obtained information about 24 hour 
urinary g-crosslinked N-telopeptides of type I collagen (NTx) as indicator of bone 
turnover. 
Type 2 Diabetes Identification 
The determination of T2DM cases in this study population was based on the 




T2DM met any of the following criteria: Single observation of plasma fasting glucose 
level greater than or equal to 126 mg/dL; current or ever anti-diabetic medication use 
indicated in the questionnaire; medical record of the diagnosis indicated in the 
questionnaire; or a 2 hour standardized glucose tolerance test value " 200 mg/dL. All 
the identified cases were classified as T2DM with cases evaluated at each clinical visit.  
Other Information 
Factors with regard to gaining effect estimates precisions or to controlling for 
confounding effect were body mass index (BMI), current smoking status, physical 
activity, educational level, and birthdates. This information was obtained via a series of 
questionnaires that were applied at the recruitment and during the follow-up clinical 
visits. BMI were derived from weight in kilogram divided by height in meter squared 
measured at each clinical visit.   
Urinary g crosslinked N-telopeptides of type I collagen (NTx ) levels were 
measured using archived 24-hour urine samples collected in 1987. NTx concentrations 
were measured via commercially available competitive-inhibition enzyme-linked 
immunosorbent assay32. Urinary NTx concentration was normalized to urinary creatinine 
secretion and is expressed as of nanomoles of bone collagen equivalents per mmol 
creatinnine (nM BCE/mM creatinine).  
Statistical Analyses  




All statistical analysis was performed in R version 2.15 33. The R survival 
package was applied for survival analysis 34. Univariate analyses were performed to 
examine the distribution of variables of interest. Each bone lead marker was first used 
as a continuous variable to examine a potential dose-response relationship or deviation 
from linearity. For the purpose of significance testing, bone lead levels were categorized 
at the 25th and the 75th percentile. Covariates were determined based on biological 
relevance of confounding effects, and includes educational level, calorie consumption 
from physical activity (kcal/wk), current smoking status, birth date and BMI. Physical 
activity was log-transformed due to right skewed distribution. Educational level was 
categorized into less than high school, high school graduates, and higher than high 
school groups. Subjects were grouped into three cohorts based on birthdates 
information: born before 1920, between 1920 and 1930, and after 1930.  
Bivariate analyses were conducted to compare the distributions of covariates in 
the exposure groups or by the T2DM status. Additionally, to examine bias introduced by 
potential differential attrition in the subset with bone lead information, comparisons 
between baseline health status and health behaviors were made between subjects with 
and without bone lead measures by diabetes status observed later in the study. 
Comparisons of T2DM biomarkers, blood pressure and health behaviors were 
conducted among lead exposure groups and among the three birth cohorts.  
Survival Analyses  
Nelson-Aalen estimators were constructed and graphed for crude comparisons 
among exposure groups as well as the covariates of interest. Cox’s proportional hazard 




applied for model construction. Using age as the time scale, we tested the lead effect on 
incident T2DM with two choices of modeling with regard to handling ‘healthy subject’ 
effect- hereon referred to survivor effects. First we used stratified analysis by birth 
cohort as recommended by Korn et al 35. The lead effects were estimated conditional on 
arbitrary survival functions of three birth cohorts (Model 4.1). This method does not 
assume any type of probability distribution of birth cohort variable. Alternatively, we 
applied a gamma frailty model (Model 4.2) for effect estimates. This model assumes the 
survival function as independent among three birth cohorts while being correlated within 
the cohorts. bj denotes the frailty parameter, which is the random effect of birth cohort 
variable with three levels and follows the gamma distribution. Coefficients ! in model 4.2 
estimates conditional hazard ratios of variable Z in a given birth cohort. Maximum 
likelihood of the variance of random effect was derived using Expectation–Maximization 
algorithm36. In addition, the test for clustering bj is given by a score test, which is robust 
to distribution assumptions of the frailty term. All of the survival analyses were 
performed in a longitudinal data format. The time scale was defined as age at clinical 
visit during follow-up period.  BMI and smoking status were treated as time varying 
variables whereas the rest of covariates were time invariant. All test results were 
considered as significantly different from the null hypothesis at p< 0.05. 
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Caption: i- individual 1, 2#n; j- 1, 2, 3- levels in b; b- birth cohorts; Z, exposure and/or covariates of 
interest; a- age at clinic checkup; p, number of parameters of time-varying covariates; k, number of 
parameters of time invariant covariates. 
Model 4.1: stratified survival model, bi as strata term. 




Without prior knowledge on dose response relationship, decisions have been 
made to categorize tibia and patella lead levels at 25th and 75th percentile for the 
significance tests. Penalized spline smoothing methods were applied to visually 
examine the dose-response relationships.  
Model fit was diagnosed by examinations of Martingale residuals and Schoenfeld 
residuals methods36.The PH assumptions were tested by visual examination and by the 
test of constancy provided in the R survival package, which is based on scaled 
Schoenfeld residuals and indicates violation of PH assumption at p< 0.05. Influential 
data points were detected by identifying delta beta greater than 2/"n, which equaled to 
0.33 in our analyses. Test of significance of frailty parameter $ (variance) was 
performed using score test against null hypothesis that $=0. 
Sensitivity Analyses  
We examined the effects of lead stratified by urinary NTx level analyses. Urinary 
NTx level was dichotomized at the median. Two sets of models were fitted 
independently in low (less or equals to the median) and high (higher than the median) 
urinary NTx groups. Covariates were chosen as the same in main hypothesis models.  
Results  
During a median of 15.58 follow-up years, 230 out of 878 subjects who had bone 
lead measurement developed T2DM. Table 4.1 shows baseline comparisons of 
characteristics between subjects with and without bone lead measurement by T2DM 
status. In general, compared to subjects without bone lead measurements, subjects 




the bone lead measurement group.  Further comparisons in T2DM subjects with regard 
to bone lead measurement statuses showed that subjects with bone lead measurement 
in general had late onset of T2DM, but tested worse on 2-hour glucose tolerance tests, 
and exhibited higher BMI with a corresponding higher prevalence of chronic diseases 
(data not shown).  
For subjects with bone lead measurements, we compared T2DM biomarkers and 
health behaviors among the three birth cohorts (Table 4.2). BMI gradually decreased 
from the young to the old cohorts. The younger cohorts had earlier T2DM onset: the 
averages of the onset age were 57.9 years (SD: 8.89) in the young, 64.89 years (SD: 
10.37) in the middle, and 68.3 years (SD 9.4) in the old cohorts, respectively. The 
proportions of current or ever smokers were higher in younger groups. The oldest 
cohort showed lower values on lipid and glucose metabolism tests.  
Table 4.3 shows the distributions of diabetic markers and health behaviors by 
patella bone lead levels among diabetic subjects. Patella bone lead levels were 
categorized at the 25th and 75th percentiles, which corresponded to 18 µg/g and 39 
µg/g, respectively. Compared to the lower 25th percentile group, subjects in the higher 
patella lead groups were older, yet had lower fasting glucose and cholesterol levels. 
Late onset of T2DM was observed in the higher patella lead level groups. Heavier 
smokers were more frequently observed in higher patella lead groups. Similar results 
were found in tibia lead groups (data not shown). 
Table 4.4 shows the comparisons on effect estimates of bone lead with different 




significance in the most of the patella lead models. Patella lead manifested a ceiling 
effect with respect to the risk of T2DM. It showed that the medium patella lead group 
had higher risk than the high patella lead group. The directions of effect estimates from 
these modeling approaches were consistent. Compared to the birth cohort stratified 
analysis, gamma frailty modeling did not improve statistical efficiency drastically. 
However, the result from score test confirmed significance of dependence in the frailty 
term. The magnitude of patella lead effects was increased in the models with 
adjustment on birth cohort.  In the tibia lead models, the effect estimates oscillated 
around null and none of the models found a statistically significant effect of tibia lead.  
Table 4.5 showed the result from the final models using gamma frailty modeling 
method. Compared to the lower 25th percentile bone lead group, the group in 25th to 75th 
percentile bone lead group had hazard ratios (HRs) of 1.57 (95%CI: 1.26, 1.94) in the 
patella lead model and 1.02 (95%CI: 0.83,1.25) in the tibia lead model. The HRs 
estimated from both patella and tibia lead models showed non-linear patterns in 
penalized spline smoothing plots (Figure 4.3, 4.4). In the patella lead model, the lead 
effect appeared to plateau at 30 µg/g, whereas the effect of tibia lead did not exhibit 
drastic increase at low levels and slowly declined after around 30 µg/g.  
Current smoking status was positively associated with risk of T2DM. Compared 
to current nonsmokers, the HR for a current smoker was 1.58, (95% CI: 1.17, 2.13) in 
patella lead model and 1.64, (95% CI: 1.22, 2.21) in tibia lead model. Physical activities 
showed a protective effect of T2DM in both models.  Increase in BMI was positively 




1.10, (95% CI; 1.08, 1.12) in tibia lead model. Educational level did not show significant 
impacts on T2DM risk in any of the models. 
After stratifying by urinary NTx levels, lead effect in the low NTx group showed 
an increased dose-response relationship, while in the higher NTx group lead effect 
estimates showed a reverse U-shape relationship (Table S 4.1). None of the lead effect 
estimates reached to statistical significance. 
Discussion  
In this longitudinal analysis with data on cumulative lead exposures, we found a 
significant association of incident T2DM with patella lead but not with tibia lead. Our 
analyses adjusted for smoking status, educational level, BMI, physical activity; thus the 
association with patella lead appears to be independent of these factors. We further 
examined lead effects stratified by urinary NTx levels. However, the results did not 
support the endogenous exposure suspicion. We also observed survivor effects in this 
dataset as the oldest cohort, who had the relatively higher bone lead concentrations, 
exhibited later onset of T2DM. Overall, the data supports the hypothesis that cumulative 
lead exposure increases the risk of T2DM.  
Justification of the Decisions in Survival Analyses 
Age at onset instead of time-on-study was chosen as the time scale in this 
survival analysis. We chose this because age is an important risk factor for the chronic 
diseases in longitudinal studies. Furthermore, in the case of using biomarkers to reflect 
cumulative exposure, the observed exposure level is a monotonic function of age. This 




First, age behaves as a confounder that is associated with both exposures and 
health outcomes. When applying the Cox’s regression with time-on-study scale, age 
should be adjusted in the model as in model 4.3. However, a simulation study showed 
that even with the adjustment considered, bias still cannot be eliminated 37. 
Alternatively, when using age as timescale, the effect estimate is conditional on the age 
effect; therefore the confounding effect of age can be eliminated (Model 4.4). 
Second, because the risk of T2DM showed age-dependent penetrance, age 
scale can capture the increasing trend of the disease’s hazard based on biological 
relevance therefore reflecting the true effects37. Hence the distribution of the hazard 
function on the age scale determines deviations of estimated effects from the true 
effects if other time scales were used. For instance, when the hazard function 
distribution follows exponential distribution family on the age scale, due to the 
memoryless property of exponential distributions, the effect estimates from other time 
scales behave in the same pattern as on the age scale. However, if the hazard function 
follows distributions other than exponential distribution, the effect estimates would 
behave differently between two scales (age scale and the other time scale). As a result, 
bias is introduced. The direction of the bias depends on the magnitude of the true effect 
and on the strength of correlations between the covariate (Z) and age as well as on if 
the adjustment of age was made37. 
 
Caption: t, time-on-study; a, biological age at the beginning of study; A, age at baseline; Z, variable of 




Model 4.3: time-on-study as time scale, adjusted for age at baseline  
Model 4.4: biological age as time scale without adjustment for birth cohorts 
Model 4.5: biological age as time scale stratified by birth cohorts. This model is recommended by Korn et 
al35. 
Furthermore, the PH assumption requires hazard ratio (!) to be independent of 
time. This can hardly be achieved in a longitudinal study, especially when the disease 
occurrence depending on age or when a biomarker is a function of time. In this study, 
bone lead monotonically increases with age. Similarly, BMI and smoking status varied 
along with age and were related to disease occurrence. Therefore, the PH assumption 
could barely hold if we used time-on-study as the time scale. In addition, the true 
influence of these risk factors on T2DM development varies at different stages of life. 
Therefore proportional hazard assumption could only be valid when conditioning on the 
age by treating age as timescale. Misspecifying timescale using time-on-study can lead 
to the departure from the PH assumption and introduce bias in the effect estimates. The 
direction of bias is unpredictable, and the magnitude of the bias is proportional to the 
true effect 37.  
In addition, due to the original inclusion criteria of the study, the subjects entered 
into the study were relatively healthier than the general population. This issue was 
especially pronounced in the subjects who were born before1920. Figure 4.2 shows that 
in the study subjects with bone lead measurements, those who borned earlier exhibited 
late onset of T2DM compared to subjects whom borned later. We here refer this 
survivor effect to the phenomenon that the old cohort that was selected in this study 
exhibited some extent of resistance to T2DM or to lead intoxication compared to the 
younger cohorts. We created a birth cohort variable that categorized the study 




after 1930. In order to control this survivor effect, stratification on birth cohort approach 
is recommended 35 as in Model 4.5. We tested our hypotheses in a set of models with 
different choice of adjustment for this survivor effect. Our result showed that with 
adjustment of birth cohort variable in the models generally reduced the survivor effect. 
However, the HR estimates at the higher tail of lead exposure were inevitably biased 
beyond the null.  
Lead exposure in the Etiology of Type 2 Diabetes  
Oxidative stress induced cellular dysfunction is the central pathophysiological 
mechanism involved in the genesis of metabolic disease1. Oxidative stress affects 
functions of intracellular organelles such as mitochondria and endoplasmic reticulum 
(ER). Mitochondria distress results in insufficient energy supply and deregulation of 
insulin pathway signaling 3. ER distress is the major pathological observation in 
diabetes38, which involves the induction of unfolded protein response39. As a 
consequence, ER stress response results in leptin/insulin resistance in hypothamus; 
inflammatory process in fat tissue induces, insulin secretion impairment and apoptosis 
of beta cells in pancreas 39.  
Lead induced oxidative stress can be observed in the many tissues 21, 40. For 
instances, lead binds to !-ALAD24 in erythrocytes, which leads to accumulation of !- 
aminolevulinic acid (!-ALA) in the cell cytoplasm. !-ALA is auto-oxidative at pH 7.0-8.0 
and generates free radicals 41. Lead inhibits the functions of a variety of reductases22, 25. 
Reduction in these bioactive antioxidants weakens defenses against oxidative stress. 




stimulating calcium efflux from mitochondria 27, 42. Lead depletes the calcium from ER 
and triggers the ER stress responses 4, 43.  
On the other hand, recent studies showed that osteocalcin plays an important 
role in insulin production and in improving insulin resistance 44, 45. Under the physical 
conditions, osteocalcin requires calcium binding to become bioactive. Lead ion (Pb2+) 
can displace calcium ion (Ca2+ ) at sulfhydryl ligand 42, 43 and causes osteocalcin more 
adsorptive to hydroxyapatite at much lower concentration. This leaves decreased 
proportion of bioactive osteocalcin in the circulation46. Experimental evidence also 
showed that lead suppresses the mRNA expression of osteocalcin47, 48.  
Our results supported the contention that lead increases the risk of T2DM by 
showing the increased HRs in elevated patella lead groups. However, we did not 
observe the significant impact in tibia lead models. To elucidate the temporality of lead 
effect, we explored the bone lead effect on T2DM with regard to bone turnover activity. 
Urinary NTx is a reliable biomarker for bone resorption activity and was shown to help 
identifying the endogenous exposure to lead 49. Under the high bone turnover condition, 
lead in trabecular bones mobilizes into blood and creates secondary endogenous lead 
exposure. Therefore the prominent effect in patella lead could be explained by effect of 
endogenous exposure. If this were the case, the patella lead effect would be stronger in 
high urinary NTx group. However, the results from the stratified analyses did not support 
this contention. Further investigation is needed to explain the discrepancies observed 





The findings from this analysis should be interpreted with cautions. The main 
concerns were raised from the structure of study population and the biomarker for 
cumulative lead exposure. First, as we illustrated in the discussion session, the study 
subjects recruited were relatively healthier than the general population. Loss of 
participation to bone lead assessment created a secondary sample attrition, which left 
the subjects remained in the subset slightly healthier. This issue becomes noteworthy in 
the oldest birth cohort since the most of susceptible subjects had been filtered out from 
the final dataset. Subjects in this birth cohort were less likely to be affected by the 
environmental lead exposures and were more resistant to T2DM. Secondly, due to the 
summary feature of bone lead, it was difficult to distinguish the effect of lead apart from 
the aging effect. It also created paradoxical relationship when the old cohort exhibited 
less susceptibility to lead intoxication and more resistance to the disease. In order to 
resolve this issue, we created birth cohort groups to quantify the frailties in the subjects 
that were born at different calendar periods. This method can reduce the bias in the 
effect estimates to some extent but could not completely remove the survivor bias. A 
better method should be developed to overcome this limitation in the population 
structure and to derive unbiased estimates. 
Other issues arisen from the lead exposure assessment and T2DM case 
identifications could also potentially affect the observed HRs. For example, all the DM 
cases identified in this study were classified as T2DM with a slim possibility that a few 
cases could belong to other types of DM. Additionally, the accuracy of bone lead 




uncertainties can be inflated with thicker skins, which is commonly seen in subject with 
high BMI. However the deviations of coefficient estimates from true effects with regard 
to these two issues were not well studied. Additionally, statistically significant 
associations were only observed in the patella lead models. Yet the NTx stratified test 
results did not support the endogenous exposure contention. This requires cautions 
when interpreting the lead effect with respect to the timing of lead exposure. 
Despite the limitations in our observations, our findings provided a valuable piece 
of evidence to establish the association between cumulative lead exposures and T2DM 
with a few strengths. First, this is the first study with long-term follow-ups and repeated 
measurements in health outcomes and confounding factors. It also adopted the 
biomarkers for cumulative exposure to lead, which renders higher power to detect 
biological associations. In addition, the observation of the survivor effect provided a 
piece of evidence showing the heterogeneities in the risk population with regard to the 
mechanism of lead exposure on the development of T2DM. This provokes further 
investigations on the interactions between genetic predispositions and environmental 
lead exposures in the development of T2DM.  
In conclusion, this analysis showed that cumulative exposure to lead increases 
the risk of T2DM with a ceiling effect. The observation of heterogeneities of 
susceptibility to T2DM in sub-study populations requires further investigations to 
elucidate the mechanisms of lead exposure on T2DM development. Animal studies are 






Table 4.1 Characteristics of Study Population at Baseline in T2DM and Non-T2DM Groups 19 
 T2DM Group Non-T2DM Group 
 Without Pb measure With Pb measure  Without Pb measure With Pb measure  
 Mean SD Mean SD  Mean SD Mean SD  
Age 44.6 8.6 40.06 6.95 ** 43.6 10.58 39.89 7.32 ** 
Birth Year 1921.19 8.53 1925.89 6.88 ** 1922.14 10.51 1926.25 7.41 ** 
Education           
Less than high school [N (%)] 27(0.07) - 24(0.06) 0.57  153(0.09) - 63(0.04) - * 
High school graduates [N (%)] 98(0.25) - 144(0.37)   651(0.38) - 367(0.21) -  
More than high school [N (%)] 42(0.11) - 50(0.13)   308(0.18) - 194(0.11) -  
Smoking Pack-years 19.65 18.99 16.36 18.16  19.63 19.35 15.03 17.78 ** 
Ever Smoking           
Never smoker [N (%)] 28(20.89) - 49(28.32) -  212(23.32) - 161(30.61) -  
Regular smoker [N (%)] 56(41.79) - 66(38.15) -  411(45.21) - 179(34.03) -  
Quit smoking [N (%)] 50(37.31) - 58(33.52) -  286(31.46) - 186(35.36) -  
Total Cholesterol (mg/dL) 208.93 47.79 209.79 45.47  204.39 44.69 199.69 43.8 * 
Serum Triglycerides (mg/dL) 160.19 94.64 150.79 75.98  132.11 51.37 130.19 50.56  
Fasting Glucose (mg/dL) 101.7 11.75 101.27 9.55  97.66 9.68 97.52 9.85  
2-Hour Glucose Test (mg/dL) 113.94 25.47 112.02 20.23  103.52 18.98 103.14 18.35  
Body Mass Index 26.65 3.24 26.83 3.03  25.52 2.85 25.47 2.54  
Systolic Blood Pressure (mmHg) 125.89 11.93 124.82 11.68  123.77 11.97 122.84 11.14  






                                            





Table 4.2 Comparison of Characteristics in T2DM Subjects in the Final Dataset by Birth Cohorts 
  Old   Middle   Young 20   
 N Mean (or %) SD N 
Mean 
(or %) SD N 
Mean 
(or %) SD  
Birth Year 46 1915.8 2.88 119 1925.31 2.7 65 1934.01 3.11 ** 
Education           
Less than high school [N (%)] 4 0.09 - 113 2.12 - 5 0.08 -  
High school graduate  [N (%)] 25 0.58 - 15 0.13 - 49 0.79 -  
More than high school [N (%)] 14 0.33 - 70 0.62 - 8 0.13 -  
Smoking Pack-years 29 14.99 18.98 28 0.25 23.27 46 21.12 19.05  
Current Smoker [N (%)] 1 0.03 - 8 0.08 - 5 0.09 -  
Former Smoker [N (%)] 17 0.49 - 67 0.67 - 38 0.68 -  
Total HDL (mg/dL) 30 46.67 11.57 87 44.76 11.67 51 42.92 11.34  
Total Cholesterol (mg/dL) 46 229.07 52.14 119 235.51 51.33 65 226.74 47.61  
Serum Triglycerides (mg/dL) 46 147.24 58.48 116 198.17 111.59 63 185.68 81.87 ** 
Fasting Glucose (mg/dL) 46 132 48.67 118 131.84 36.2 65 133.52 38.77  
2-Hour Glucose Test (mg/dL) 40 197.1 47.62 103 198.07 70.59 59 224.51 87.25  
Body Mass Index 35 26.49 3.81 101 29.41 4 65 30.95 4.59 ** 
Systolic Blood Pressure (mmHg) 46 138.67 17.82 119 135.27 17.65 65 135.74 19.3  
Diastolic Blood Pressure (mmHg) 46 80.62 10.01 119 80.43 9.28 65 83.18 9.91  
Physical Activity (Fast walk adjusted, kcal/wk) 22 1806.32 1160.07 67 1290.29 1231.95 42 1285.13 1137.74  
Physical Activity (No fast walk, kal/wk) 22 1251.89 827.05 67 1200.41 1181.74 42 1193.86 1072.4  
Diabetes Diagnosis [N (%)] 46 0.22 - 119 0.17 - 65 0.25 -  
Diabetes Medication (Current) [N (%)] 45 0.02 - 119 0.09 - 65 0.05 -  
Diabetes Onset Age 23 68.3 9.44 58 64.89 10.37 38 57.9 8.89 ** 
 
                                            
20 The old cohorts were born before 1920; the middle cohort was born between 1920 and 1930; the young cohort was born later than 1930. p 




Table 4.3 Comparison of Characteristics in T2DM Subjects by Patella Lead Groups 21 
 !25 percentile (!18 µg/g) 
25-75 percentile 
(18 -39 µg/g) 
>75 percentile 
(>39 µg/g)  
 N Mean SD N Mean SD N Mean SD  
Birth Year 46 1928.51 7.32 117 1926.68 6.09 67 1922.63 6.79 ** 
Education           
Less than high school [N (%)] 4 0.09 - 15 0.13 - 5 0.08 - ** 
High school graduate [N (%)] 25 0.58 - 70 0.62 - 49 0.79 -  
More than high school [N (%)] 14 0.33 - 28 0.25 - 8 0.13 -  
Smoking Pack-years 27 20.96 18.3 85 22.06 22.26 40 23.73 22.45  
Current Smoker [N (%)] 37 0.11 - 100 0.08 - 54 0.04 -  
Former Smoker [N (%)] 37 0.62 - 100 0.62 - 54 0.69 -  
Total HDL (mg/dL) 32 44.94 10.53 89 44.2 11.74 47 44.91 12.07  
Total Cholesterol (mg/dL) 46 222.13 48.18 117 231.81 49.91 67 238.22 52.44  
Serum Triglycerides (mg/dL) 45 154.91 62.38 114 193.82 105.27 66 187.77 97.17  
Fasting Glucose (mg/dL) 46 134.65 44.72 117 132.26 43.77 66 130.91 25.92  
2-Hour Glucose Test (mg/dL) 43 215.7 73.65 100 200.19 73.32 59 207.41 71.97  
Body Mass Index 41 30.89 5.03 106 29.11 4.24 54 28.83 4.06 * 
Systolic Blood Pressure (mmHg) 46 141.5 17.57 117 132.21 18 67 139.12 17.45 ** 
Diastolic Blood Pressure (mmHg) 46 83.92 8.18 117 80.24 10.64 67 81.17 8.43  
Physical Activity (No fast walk, kal/wk) 26 1511.92 1041.61 65 1046.14 1049.84 40 1270.05 1152.68  
Diabetes Diagnosis [N (%)] 10 0.22 - 24 0.21 - 12 0.18 -  
Diabetes Medication (Current) [N (%)] 4 0.09 - 8 0.07 - 3 0.05 -  
Diabetes Onset Age (Self-Reported) 23 60.74 11.39 63 62.52 10.55 33 66.64 8.9  





                                            






Table 4.4 Comparison of Coefficients in Tibia and Patella Lead Models22 
 Patella Lead Models  
 Q1 (!18"g/g) Q2-Q3 (18 –39"g/g)  Q4 (>39 "g/g)  p for trend 
N  221 437  214   
Events  46 117  67  0.01 
Model 1 - 0.17 (0.08) * 0.06(0.09)  0.74 
Model 2 - 0.40(0.11) ** 0.28(0.12) * 0.05 
Model 3 - 0.45(0.11) ** 0.39(0.12) ** <0.01 
Model 4 - 0.45(0.11) ** 0.39 (0.12) ** 0.11 
 Tibia Lead Models  
 Q1 (!13 "g/g) Q2-Q3 (13 –28"g/g)  Q4 (>28 "g/g)  p for trend 
N 230 443  204   
Events 51 118  61  0.07 
Model 1 - 0.02(0.08)  0.042(0.09)  0.64 
Model 2 - -0.02 (0.10)  -0.051(0.12)  0.67 
Model 3 - 0.01 (0.10)  0.051(0.12)  0.67 








                                            
22 Major covariates: current smoking status, physical activity, educational level, and BMI. Model 1: crude lead effect estimate; Model2: adjusted for 
major covariates; Model3: stratified on birth cohort; Model4: gamma frailty model, birth cohort as frailty term; p values (not presented in the table) 





Table 4.5 Hazard Ratios and 95% Confidence Intervals in the Final Models23 
 Patella Lead Model 24 Tibia Lead Model25 
 HR LCI UCI HR LCI UCI 
Lead (25th -75th percentile)  1.57 1.26 1.94 1.02 0.83 1.25 
Lead (>75th percentile)  1.48 1.16 1.89 1.05 0.83 1.34 
Current Smoker 1.58 1.17 2.13 1.64 1.22 2.21 
Physical Activity Expended (kcal/wk) 0.81 0.74 0.87 0.79 0.73 0.86 
Body Mass Index 1.11 1.09 1.13 1.10 1.08 1.12 
Education: High school graduate 1.11 0.86 1.44 1.10 0.85 1.42 












                                            
23 The frailty terms in both models were significant  
24 Patella lead at 25th and 75th percentiles corresponded to 18 µg/g and 39 µg/g 






Table S 4.1 Lead Effects Stratified by Urinary NTx Levels26 
  Tibia lead Models27 Patella lead Models28 
 Lead Levels Low NTx (!50%)29 High NTx (>50%) Low NTx (!50%) High NTx (>50%) 
  ! Se(!) p value ! Se(!) p value ! Se(!) p value ! Se(!) p value 
Model 1 25th -75th percentile 0.04 0.16 0.81 0.13 0.19 0.47 0.31 0.18 0.08 0.16 0.18 0.38 
 > 75th percentile 0.23 0.19 0.22 0.07 0.22 0.74 0.47 0.20 0.02 0.02 0.21 0.93 
Model 2 25th -75th percentile 0.04 0.16 0.83 0.11 0.19 0.55 0.32 0.18 0.08 0.16 0.19 0.40 
 > 75th percentile 0.23 0.19 0.21 0.06 0.22 0.77 0.47 0.20 0.02 0.02 0.21 0.92 
Model 3 25th -75th percentile 0.03 0.16 0.86 0.17 0.18 0.34 0.23 0.18 0.18 -0.01 0.17 0.96 









                                            
26 Major covariates: current smoking status, physical activity, educational level, and BMI. Model1: Cox’s model, birth cohort as covariate; Model 2: 
Cox’s model, stratified on birth cohort; Model 3: gamma frailty model, birth cohort as frailty term. 
27 Tibia lead at 25th and 75th percentiles corresponded to 13 µg/g and 28 µg/g 
28 Patella lead at 25th and 75th percentiles corresponded to 18 µg/g and 39 µg/g 






Figure 4.1 Event Timeline in NAS (Frequency Density Plot) 
Caption: The majority of the study subjects were born in early 1900’s (blue dashed line). 
They were recruited beginning in the early 1960’s with continuous enrollment until early 
1970’s (solid line). Physical checkups were performed every three years for each 
subject 50 or older and every five years for subjects younger than 50. Bone lead 
measurements were added to the study in 1991 and were continued until 2002 (red 
dotted line). Diabetes incidence, represented by the black dash line, rose from early 
1960’s till the end of study period. For purpose of this analysis, the density plot 
presented in this graph is limited to the subjects in the current study. The total number 





Figure 4.2 Survivor Effect (T2DM Onset vs. Birth Year) 
Caption: X-axis: the birthdates of study subjects in calendar years. Y-axis: the age at 







Figure 4.3 Hazard Ratios vs. Tibia Lead Levels  
Caption: X-axis: the tibia lead level in µg/g. Y-axis: the hazard ratios estimated from the 




Figure 4.4 Hazard Ratios vs. Patella Lead Levels 
Caption: X-axis: the patella lead level in µg/g. Y-axis: the hazard ratios estimated from 
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5. CHAPTER 5 CONCLUSIONS 
Lead exposure remains an enormous public health problem worldwide. Evidence 
from basic science, clinical and epidemiological studies has provided fundamental 
knowledge on the toxic effects of lead exposure on human health.  A majority of the 
epidemiologic research has focused on the cross-sectional links between lead 
exposures and health outcomes. In the handful of longitudinal studies, researchers have 
found that the effects of lead can be long lasting1, 2. Yet limited research has addressed 
the issue of timing of exposure to lead with respect to health outcomes in the long term. 
In this dissertation, I investigated the effect of exposure to lead in terms of windows of 
exposures. With the advantage of longitudinal study designs and the use of biomarkers 
for cumulative as well as short-term lead exposures, I aimed to establish the 
relationship between exposure to lead and a variety of health outcomes regarding the 
timing of lead exposure.  The scope of health outcomes in this thesis covered 
psychobehavioral development, degenerative neurological disease (Parkinson’s 
disease) and type 2 diabetes. Specifically, I investigated the timing of exposure to lead 
in the perinatal period and in early life in relation to the psychobehavioral development 
in children aged from 6 to 13 in Chapter 2. Chapter 3 and Chapter 4 focused on the 
potential influence of lifetime exposures to lead on risk of diseases that typically occur in 
late life. The goal of Chapter 3 was to understand the potential impact of lifetime 
exposure to lead on Parkinson’s disease occurrence in subjects with genetic 
predisposition to Parkinson’s disease in relation to polymorphisms of the SNCA gene. 
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Chapter 4 aimed to discover the relationship between lifetime lead exposure and risk of 
type 2 diabetes. All three chapters together attempted to assess the temporal dynamics 
of the influence of lead exposures across the lifespan.  
In Chapter 2, the results did not show statistically significant associations 
between lead exposures in early life and behavioral outcomes measured in childhood/ 
early adolescence. However, the data suggested that exposure to lead during the 
prenatal period and the first two years after birth have strong impacts on inattention and 
hyperactivity behaviors. It appeared to affect emotion controls and somatic perceptions 
in children. Compared to effects of exposures during the perinatal period, the effect of 
recent lead exposure did not show strong impact on children’s behaviors. These 
findings can be explained in relation to two respects. First, during early life, the 
immature brain does not have the protective mechanism to prevent against lead 
poisoning 3-5. Previous studies have shown that the immature brain is a particularly 
sensitive target for lead poisoning. Second, the limbic system, of which functions are 
involved in emotional memory and socialization, develops and matures quickly in the 
first three years of life 6, 7 
However the limitations in these observations are that, first, the exposure levels 
in perinatal period was relatively higher than the recent lead exposure levels and 
second, these observations were limited to the subjects who had complete exposure 
measurements over the years of observation, which rendered a significant drop in 
sample size. This decreased the study’s power. Third, the psychobehavioral 
assessments were only performed at one time point. We do not have observations of 
behavioral change overtime as a function of early life lead exposure. Future research 
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may need to clarify the effects of the temporal exposure patterns on a larger scale, as 
well as to provide new understanding on effect of timing of lead exposures on 
psychobehavioral development as a dynamic growing process. Nevertheless, this study 
provides an importance piece of evidence demonstrating the critical windows of lead 
exposures on the neurodevelopment in a long term.  
In Chapter 3, I focused on the effect of lead from cumulative exposure on 
Parkinson’s disease under different levels of genetic susceptibility. I investigated the 
lead effect among SNCA genetic variants on the disease occurrence. After counting for 
linkage disequilibrium, I found three loci that strongly predicted Parkinson’s disease.  
Lead increases the odds of PD only among subjects who were genetically relatively 
resistant to the disease. Subjects with higher genetic susceptibility were less affected by 
lead exposure. This result implies that lead exposure and genetic predisposition in 
SNCA gene does not have a synergistic effect on PD development. In addition, I did not 
observe that genotypes of SNCA were strongly associated with bone lead levels. This 
indicates that SNCA gene does not modify the toxicodynamic of lead. These findings on 
the main effects of genetic markers were consistent with current knowledge on genetic 
etiology to PD8-17. However the main effects of lead were attenuated compared to our 
previous findings from a bigger sample18.  In addition, this result showed that tibia lead 
appeared to be associated with PD when combined with genetic information more 
frequently than patella lead. This may be due to the low decay rate of cortical bone lead 
19. This underscores the importance of cumulative exposure to lead exposure on PD 
development, a topic that has been discussed in detail in our previous publications18.  
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The mechanism of how lead exposures may cause Parkinson’s disease is not 
clearly understood. The current conceptual framework involves oxidative stress 20-22and 
alpha synuclein aggregation 23-27in dopamine neurons. The result however was not in 
support of the idea of lead aggravating the effects of deleterious genetic variants of the 
SNCA gene. While these results are clearly preliminary, and are in need of replication, 
along with other work to better understand the pathogenesis of PD. 
Chapter 4 provided novel evidence that exposure to lead could affect energy 
metabolism and result in type 2 diabetes. I found a significant increase of T2DM risk 
with an incremental increase in patella lead levels. I observed a discrepancy between 
the tibia lead and the patella lead effects on T2DM development. The NTx stratified 
analysis results did not support the contention that secondary endogenous lead 
exposure from increased resorption of bone stores of lead plays a significant role in 
modifying the effects of bone lead. These findings suggested that cumulative exposure 
to lead increases the risk of T2DM with a ceiling effect. The biological plausibility of the 
findings relates to two potential mechanisms involving inflammation and osteocalcin 
pathways. Lead imposes great oxidative stress on cells28-31and affects osteocalcin 
through calcium interference 32, 33. Lead exposure results in impaired beta cell function 
and deranged osteocalcin hemostatsis, which may result in the perturbations of lipid 
and glucose metabolism.  
The use of cumulative exposure markers posed some particular methodological 
challenges. This use carries the inherent difficulty of distinguishing the effect of the long-
term exposure apart from the aging effect. It also created paradoxical relationships 
when an older cohort exhibits decreasing susceptibility to either the exposure or the 
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disease (“survivor effect”). On the other hand, the survivor effect reflects the 
heterogeneities in risk associated with the pool of subjects with late stage T2DM.  This 
will require additional investigations on the interactions between genetic factors and 
environmental lead exposures in the etiology of T2DM. In addition, animal studies may, 
in parallel, help clarify the biological pathways of lead effects in relation to T2DM.  
The studies in this thesis provide a landscape of lead effects on human health 
across the life span with consideration of the timing of the exposures, and interactions 
with genetic vulnerabilities. It explored the associations with diseases of which 
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